%PDF-1.2
%
1 0 obj
<<
/CreationDate (D:20050926093714+02'00')
/ModDate (D:20050926093714+02'00')
/Producer (Acrobat Distiller 5.0.5 \(Macintosh\))
/Title (ONCO.2)
/Creator (QuarkXPress\(tm\) 4.1)
>>
endobj
2 0 obj
<<
/Type /Metadata
/Subtype /XML
/Length 937
>>
stream
ONCO.2
endstream
endobj
4 0 obj
<<
/Length 5539
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.73 691.61 490.35 -634.96 re
f
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.74 719.95 m
517.08 719.95 l
S
26.73 788 490.35 -56 re
f
493.07 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 507.0804 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(21)Tj
ET
0 0 0 0 k
26.73 57.65 490.35 -1 re
f
26.73 788 490.35 -56 re
f
26.73 236.27 490.35 -179.62 re
f
BT
9 0 0 9 26.7332 144.6236 Tm
0 0 0 1 k
-0.0001 Tc
(Services of)Tj
5.4 0 0 5.4 26.7332 136.8403 Tm
0 Tc
(1)Tj
9 0 0 9 31.6832 133.8703 Tm
(Oncologa Mdica)Tj
5.4 0 0 5.4 26.7332 126.0869 Tm
(2)Tj
9 0 0 9 31.6832 123.1169 Tm
(Bioqumica y Anlisis Clnicos)Tj
-0.55 -2.3896 TD
-0.0001 Tc
(Hospital Regional Universitario Carlos Haya)Tj
0 -1.1948 TD
0 Tc
(Mlaga)Tj
0 -2.3896 TD
(Recibido: 24.06.05)Tj
0 -1.1948 TD
(Aceptado: 04.07.05)Tj
ET
0 0 0 0 k
26.73 691.61 490.35 -33.61 re
f
BT
12 0 0 12 26.7332 683.4002 Tm
0 0 0 1 k
-0.0001 Tc
(Original)Tj
ET
0 0 0 0 k
26.73 653.99 490.35 -129.63 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
16 0 0 16 26.7332 613.147 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Changes in the serum amino acids concentrations after first cycle )Tj
0 -1.125 TD
[(as a factor pr)17.7(edictive of tumor r)17.7(esponse to chemotherapy )]TJ
10 0 0 10 79.483 569.339 Tm
(M. Cobo-Dols)Tj
6 0 0 6 138.9142 572.639 Tm
0 Tc
(1)Tj
10 0 0 10 141.9142 569.339 Tm
(, E. Prez-Miranda)Tj
6 0 0 6 223.5475 572.639 Tm
(2)Tj
10 0 0 10 226.5475 569.339 Tm
-0.0001 Tc
(, S. Gil-Calle)Tj
6 0 0 6 280.9836 572.639 Tm
0 Tc
(1)Tj
10 0 0 10 283.9836 569.339 Tm
-0.0001 Tc
(, I. Als-Daz)Tj
6 0 0 6 338.9616 572.639 Tm
0 Tc
(1)Tj
10 0 0 10 341.9617 569.339 Tm
-0.0001 Tc
(, E. Villar-Chamorro)Tj
6 0 0 6 431.9348 572.639 Tm
0 Tc
(1)Tj
10 0 0 10 434.9348 569.339 Tm
-0.0001 Tc
(, A. Montesa-Pino)Tj
6 0 0 6 511.5803 572.639 Tm
0 Tc
(1)Tj
10 0 0 10 514.5804 569.339 Tm
(, )Tj
-26.1153 -1.2904 TD
(J. Alcaide Garcia)Tj
6 0 0 6 327.5725 559.735 Tm
(1)Tj
10 0 0 10 330.5725 556.435 Tm
-0.0001 Tc
(, F. Carabante-Ocn)Tj
6 0 0 6 418.3264 559.735 Tm
0 Tc
(1)Tj
10 0 0 10 421.3264 556.435 Tm
-0.0001 Tc
(, M. Benavides-Orgaz)Tj
6 0 0 6 514.0803 559.735 Tm
0 Tc
(1)Tj
ET
0 0 0 0 k
26.73 510.19 490.35 -267.17 re
f
BT
14 0 0 14 26.7332 486.6153 Tm
0 0 0 1 k
-0.0002 Tc
(Summary)Tj
13 0 0 13 37.4765 458.6153 Tm
0.0001 Tc
0.1248 Tw
( Objective:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 108.7868 458.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0696 Tc
0 Tw
(To)Tj
1.0413 0 TD
( )Tj
0.3749 0 TD
0.0001 Tc
0.1248 Tw
[(detect variations of the serum amino acids \(AA\) profile in cancer patients under)17.4(going)]TJ
-8.8757 -1.2727 TD
0 Tc
0 Tw
(chemotherapy to identify factors predicting the response to treatment.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 37.4765 430.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0089 Tw
( Material and methods:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 175.539 430.6153 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0089 Tw
(In 54 patients with lung, head and neck, and germ cell tumors, the circulating)Tj
-13.5278 -1.2727 TD
0.0085 Tc
0.1165 Tw
(concentrations of 27 AA were prospectively measured at the basal line and following each chemotherapy)Tj
T*
0 Tc
0 Tw
(cycle. )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 37.4765 388.6153 Tm
0 0 0 1 k
/GS1 gs
0.0081 Tc
0.1167 Tw
( Results: )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 97.5049 388.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0715 Tc
0 Tw
(We)Tj
1.3245 0 TD
( )Tj
0.375 0 TD
0.0083 Tc
0.1167 Tw
(observed changes in the majority of the AA following the first chemotherapy cycle in)Tj
-8.1332 -1.2727 TD
0.0151 Tc
0.1099 Tw
[(relation to the basal line. These changes were greater in those patients who responded to chemotherapy)65(.)]TJ
T*
0.0001 Tc
0.1249 Tw
(Following the first chemotherapy cycle, the per cent increase with regard to the base line was significantly)Tj
T*
0 Tc
0 Tw
(greater for 17 AA in subjects responding to therapy when compared with those who did not respond.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 37.4765 332.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0002 Tc
0.0106 Tw
( Conclusions:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 119.7749 332.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0106 Tw
[(In patients responding to therapy)64.9(, a rapid rise of the majority of the AA following the first)]TJ
-8.4583 -1.2727 TD
0 Tc
0 Tw
[(cycle appears to be an early indicator of tumor response to cisplatin-containing chemotherapy)65(.)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 37.4765 290.6153 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Key words:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.4765 276.6152 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
[(Amino acids. Chemotherapy)65(. T)34.9(umor response)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 37.4866 248.6153 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(Oncologa, 2005; 28 \(7\):321-328)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.73 168.61 m
131.67 168.61 l
S
Q
endstream
endobj
5 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
10 0 obj
<<
/FunctionType 0
/Domain [0 1]
/Range [0 1]
/BitsPerSample 8
/Size [256]
/Length 271
/Filter /FlateDecode
>>
stream
H
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~
endstream
endobj
12 0 obj
<<
/Length 9641
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 26.7705 397.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Intr)17.7(oduction)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.5138 371.9843 Tm
0 0 0 1 k
/GS1 gs
0.0224 Tc
0.1025 Tw
(Amino acids \(AA\) are simple monomeric sub-)Tj
-0.9767 -1.1818 TD
0.0032 Tc
0.1218 Tw
(units composed of a carboxyl group and an amino)Tj
T*
0 Tc
0.0789 Tw
(group bound to the same carbon atom)Tj
6.6 0 0 6.6 198.1522 349.6143 Tm
0 Tw
(1)Tj
11 0 0 11 201.4522 345.9843 Tm
0.0789 Tw
(. The 20 AA)Tj
-15.8802 -1.1818 TD
0.0069 Tw
(of the proteins are usually termed standard)Tj
6.6 0 0 6.6 224.5194 336.6143 Tm
0 Tw
(2)Tj
11 0 0 11 227.8195 332.9843 Tm
0.0069 Tw
(. There)Tj
-18.2772 -1.1818 TD
0.085 Tw
(are 5 principal AA groups: the apolar aliphatic R)Tj
T*
0.019 Tc
0.106 Tw
[(groups, the aromatic groups, the unchar)17.7(ged polar)]TJ
T*
0 Tc
0.0319 Tw
[(groups, the negatively char)17.8(ged groups, and the posi-)]TJ
T*
0.0335 Tc
0.0914 Tw
[(tively char)17.7(ged groups)]TJ
6.6 0 0 6.6 131.6292 284.6143 Tm
0 Tc
0 Tw
(3)Tj
11 0 0 11 135.1506 280.9843 Tm
0.0335 Tc
0.0915 Tw
(. Ion exchange chromato-)Tj
-9.8527 -1.1818 TD
0 Tc
0.0326 Tw
(graphy is the most used method to separate, identify)Tj
T*
0 Tw
(and quantify each of the AA present in a mixture)Tj
6.6 0 0 6.6 242.0949 258.6143 Tm
(4)Tj
11 0 0 11 245.395 254.9843 Tm
(.)Tj
-18.8983 -1.1818 TD
0.0729 Tw
(The metabolic processes in the cancer patient are)Tj
-0.9767 -1.1818 TD
0.0512 Tw
[(substantially dif)17.8(ferent to normal subjects with pecu-)]TJ
T*
0.1009 Tw
(liarities in the metabolism of the principal interme-)Tj
T*
0.0006 Tc
0.1244 Tw
(diates, not only with carbohydrates)Tj
6.6 0 0 6.6 186.7441 206.6143 Tm
(5, 6)Tj
11 0 0 11 201.6069 202.9843 Tm
(and fats)Tj
6.6 0 0 6.6 237.5406 206.6143 Tm
0 Tc
0 Tw
(7)Tj
11 0 0 11 244.9698 202.9843 Tm
0.0006 Tc
(but)Tj
-19.8363 -1.1818 TD
0 Tc
0.0013 Tw
(also with the proteins. The alterations of the AA me-)Tj
T*
0.1049 Tw
[(tabolism and of the proteins in the or)17.8(ganism of the)]TJ
T*
0.0459 Tw
(patients with cancer are a consequence of metabolic)Tj
T*
0.0203 Tc
0.1047 Tw
(dysfunction, such as accelerated gluconeogenesis)Tj
T*
0 Tc
0.0067 Tw
(and the increase in the synthesis of proteins in the li-)Tj
T*
-0.0001 Tc
0 Tw
(ver)Tj
6.6 0 0 6.6 40.8132 128.6143 Tm
0 Tc
(8)Tj
11 0 0 11 44.1132 124.9843 Tm
0.091 Tw
(. The degree of change in the pattern of the se-)Tj
-1.5766 -1.1818 TD
0.0277 Tc
0.0973 Tw
(rum AA in cancer patients depends on variables)Tj
T*
0 Tc
0.0857 Tw
[(such as: the specific type of tumor)39.8(, the stage of the)]TJ
T*
0.0166 Tc
0.1084 Tw
(disease and its extent, and the presence or not of)Tj
T*
0 Tc
0.0869 Tw
(protein-caloric malnutrition)Tj
6.6 0 0 6.6 149.5918 76.6143 Tm
0 Tw
(9)Tj
11 0 0 11 152.8918 72.9843 Tm
-0.0001 Tc
0.087 Tw
(. The analysis of serum)Tj
-11.4656 -1.1818 TD
0.0246 Tc
0.1003 Tw
[(AA in the dif)17.8(ferent studies conducted have been)]TJ
23.4616 30.7273 TD
0 Tc
0.0993 Tw
(complicated by the heterogeneity of the neoplasias,)Tj
0 -1.1818 TD
0.0156 Tc
0.1093 Tw
[(as well as the dif)17.7(ference in response to treatment)]TJ
T*
0 Tc
0 Tw
(employed)Tj
6.6 0 0 6.6 328.2249 375.6143 Tm
(10)Tj
11 0 0 11 334.8249 371.9843 Tm
(.)Tj
-3.5667 -1.1818 TD
0.0601 Tw
[(The concentrations of some of the serum AA can)]TJ
-0.9767 -1.1818 TD
0.1124 Tw
(be specific in relation to the type of tumor and ac-)Tj
T*
0.0708 Tw
(cording to the quality of influence on the metabolic)Tj
T*
0.0102 Tc
0.1147 Tw
(status of the host)Tj
6.6 0 0 6.6 364.9012 323.6143 Tm
0 Tc
0 Tw
(1)Tj
0.4488 0 TD
0.0103 Tc
0.1147 Tw
(1, 12)Tj
11 0 0 11 382.1598 319.9843 Tm
0.1148 Tw
(. The concentrations of these)Tj
-8.8465 -1.1818 TD
0 Tc
0.0169 Tw
(AA have been observed to return to their normal va-)Tj
T*
0.032 Tw
[(lues after an ef)17.8(ficacious therapy change again on di-)]TJ
T*
-0.0001 Tc
0.1246 Tw
(sease relapse)Tj
6.6 0 0 6.6 343.3132 284.6143 Tm
0 Tc
0 Tw
(13)Tj
11 0 0 11 349.9133 280.9843 Tm
0.1246 Tw
(. In murine models, specific patterns)Tj
-5.915 -1.1818 TD
0.0036 Tc
0.1214 Tw
(of AA profile have been observed in the serum of)Tj
T*
0 Tc
0.1237 Tw
[(rats that have had a specific tumor)19.8(-type implanted,)]TJ
T*
0.075 Tc
0.3539 Tw
(and which normalizes when the tumor is)Tj
T*
0 Tc
0 Tw
(extirpated)Tj
6.6 0 0 6.6 328.8238 232.6143 Tm
(14)Tj
11 0 0 11 335.4238 228.9843 Tm
0.045 Tw
[(. In lung cancer)39.8(, the increase in glutamic)]TJ
-4.5978 -1.1818 TD
0.0921 Tw
[(acid can be the result of an inef)17.8(ficient use of nitro-)]TJ
T*
0.0403 Tw
(gen since the tumor acts as a nitrogen trap)Tj
6.6 0 0 6.6 483.2525 206.6143 Tm
0 Tw
(15)Tj
11 0 0 11 489.8525 202.9843 Tm
(,)Tj
0.4242 0 TD
(com-)Tj
-19.061 -1.1818 TD
0.0245 Tc
0.1005 Tw
(peting with the host for nitrogenous components)Tj
T*
0.0179 Tc
0.1071 Tw
[(that are needed for its own protein synthesis; the)]TJ
T*
0.0041 Tc
0.1209 Tw
(glutamic acid being normalized when the tumor is)Tj
T*
0 Tc
0 Tw
(extirpated)Tj
6.6 0 0 6.6 328.8238 154.6143 Tm
(16)Tj
11 0 0 11 335.4238 150.9843 Tm
0.0085 Tw
(. Similar observations have been made in)Tj
-4.5978 -1.1818 TD
0 Tw
(several studies in humans)Tj
6.6 0 0 6.6 397.563 141.6143 Tm
-0.0001 Tc
(17-22)Tj
11 0 0 11 412.9594 137.9843 Tm
0 Tc
(.)Tj
-10.6698 -1.1818 TD
0.109 Tw
(Hence, change in the levels of AA can have im-)Tj
-0.9767 -1.1818 TD
0.0132 Tc
0.1118 Tw
(portance in the clinical management of malignant)Tj
T*
0.0135 Tc
0.1115 Tw
(neoplasias in that they can be used as markers of)Tj
T*
0.0104 Tc
0.1146 Tw
(response to the oncologic treatment, as well as of)Tj
T*
-0.0001 Tc
0.0355 Tw
(early recurrence during follow-up)Tj
6.6 0 0 6.6 434.7313 76.6143 Tm
0 Tc
0 Tw
(23)Tj
11 0 0 11 441.3313 72.9843 Tm
-0.0001 Tc
0.0354 Tw
(. In our study we)Tj
-14.2258 -1.1818 TD
0.0086 Tc
0.1163 Tw
(analyzed variations of the profile of serum AA of)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.77 719.95 m
517.12 719.95 l
S
0 0 0 0 k
26.77 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 26.7705 734.168 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(M. Cobo-Dols y cols.)Tj
ET
0 0 0 0 k
26.77 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 26.7705 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(22)Tj
ET
0 0 0 0 k
26.77 691.61 490.35 -276.61 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 26.7705 682.0326 Tm
0 0 0 1 k
/GS1 gs
-0.0002 Tc
0 Tw
(Resumen)Tj
13 0 0 13 37.5138 654.0326 Tm
-0.0001 Tc
0.114 Tw
( Objetivo:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 103.4966 654.0326 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.114 Tw
[(Detectar variaciones en el perfil de AA sricos de pacientes neoplsicos sometidos a trata-)]TJ
-6.9751 -1.2727 TD
0 Tw
(miento quimioterpico, e intentar encontrar factores predictivos de respuesta tumoral.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 37.5138 626.0326 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0212 Tw
( Material y mtodos:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 161.0127 626.0326 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0212 Tw
(En 54 pacientes con carcinoma de pulmn, cabeza y cuello y geminales sin alte-)Tj
-12.2038 -1.2727 TD
0.102 Tw
(raciones metablicas ni otras patologas concomitantes se determinaron prospectivamente los niveles sricos)Tj
T*
0 Tw
(basales de 27 aa diferentes y se analizan basalmente y tras cada ciclo de quimioterapia. )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 37.5138 584.0326 Tm
0 0 0 1 k
/GS1 gs
-0.0002 Tc
0.0566 Tw
( Resultados:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 114.403 584.0326 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0565 Tw
(Observamos modificaciones en la mayora de los AA medidos tras el primer ciclo de qui-)Tj
-7.9666 -1.2727 TD
0.0285 Tw
(mioterapia respecto a su nivel basal. Estas modificaciones fueron ms ostensibles en sujetos con respuesta a la)Tj
T*
0.0363 Tw
(quimioterapia. La variable porcentaje de incremento de los AA \(calculada teniendo en cuenta la diferencia del)Tj
T*
0.0531 Tw
(nivel de aa tras el primer ciclo de quimioterapia respecto al nivel basal\) fue significativamente superior en 17)Tj
T*
-0.0001 Tc
0 Tw
(AA en sujetos respondedores frente a los no respondedores.)Tj
0.9767 -1.2727 TD
-0.0002 Tc
( )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
13 0 0 13 44.7334 514.0325 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Conclusiones: )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 125.9845 514.0325 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0565 Tw
(La elevacin brusca de la mayora de los aminocidos tras el 1 ciclo de quimioterapia,)Tj
-9.0195 -1.2727 TD
0 Tw
(parece ser indicador predictivo precoz de respuesta tumoral.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 37.5138 472.0326 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0001 Tw
(Palabras clave:)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 112.0457 472.0326 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(Aminocidos. Qumioterapia. Respuesta tumoral)Tj
ET
Q
endstream
endobj
13 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
15 0 obj
<<
/Length 11272
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.73 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 26.7332 683.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0783 Tw
[(patients with cancer under)17.8(going chemotherapy with)]TJ
0 -1.1818 TD
0.0219 Tw
(the intent of early identification of factors predictive)Tj
T*
0 Tw
(of early tumor response to treatment. )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 26.7332 618.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Materials and methods)Tj
11 0 0 11 26.7332 592.9843 Tm
(Patient selection)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.4765 566.9843 Tm
0 0 0 1 k
/GS1 gs
0.0125 Tc
0.1125 Tw
(The study was prospective and included 54 pa-)Tj
-0.9767 -1.1818 TD
0 Tc
0.029 Tw
(tients with the diagnosis of cancer of the lung or he-)Tj
T*
0.0159 Tc
0.1091 Tw
[(ad & neck beyond sur)17.8(gery)65(, and testicular tumors.)]TJ
T*
0.0239 Tc
0.1011 Tw
(The patients were treated in a single centre with)Tj
T*
0 Tc
0.0902 Tw
(chemotherapy based on cisplatin. The selection cri-)Tj
T*
0.0013 Tc
0.1236 Tw
(teria were: age between 18-70 years; ECOG status)Tj
T*
0.0092 Tc
0.1158 Tw
(<2; weight loss <5%; measurable disease; no pre-)Tj
T*
0 Tc
0.0587 Tw
(vious chemotherapy; no concomitant endocrine-me-)Tj
T*
0.003 Tc
0.122 Tw
(tabolic disorders or non-controlled hypertension or)Tj
T*
0 Tc
0.1137 Tw
(infections. Hepatic, renal cardiac and bone marrow)Tj
T*
0.0117 Tc
0.1133 Tw
(function needed to be normal and the patient was)Tj
T*
0 Tc
0.0057 Tw
(not to be receiving food supplements; neither enteral)Tj
T*
0 Tw
(nor parenteral. )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 26.7332 384.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Therapeutic pr)17.7(otocol)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.4765 358.9843 Tm
0 0 0 1 k
/GS1 gs
0.005 Tc
0.0256 Tw
(In all the cases, cisplatin was employed at the sa-)Tj
-0.9767 -1.1818 TD
0.081 Tw
(me dose of 100 mg/m)Tj
6.6 0 0 6.6 127.2707 349.6143 Tm
0 Tc
0 Tw
(2)Tj
11 0 0 11 134.3 345.9843 Tm
0.005 Tc
0.081 Tw
(in cycles repeated every 21)Tj
-9.7788 -1.1818 TD
0.0476 Tw
(days. The type of chemotherapy employed was cis-)Tj
T*
0.0608 Tw
(platin + etoposide in all the patients with lung can-)Tj
T*
0.0312 Tc
0.0988 Tw
(cer; cisplatin + 5-fluorouracil in all the patients)Tj
T*
0.005 Tc
0.0312 Tw
(with head & neck cancer and the BEP \(Bleomicine,)Tj
T*
0.0039 Tw
(Etoposide, Cisplatin\) scheme in all the patients with)Tj
T*
0.0417 Tw
(germinal cell tumors. The chemotherapy was admi-)Tj
T*
0.0111 Tc
0.1189 Tw
(nistered in hospital. Prior to the administration of)Tj
T*
0.005 Tc
0.0106 Tw
[(each cycle of chemotherapy)65(, a blood sample was ta-)]TJ
T*
0.0097 Tc
0.1203 Tw
(ken for analysis \(hemogram, glycemia, creatinine,)Tj
T*
0.0118 Tc
0.1182 Tw
[(electrolytes\). W)79.9(e)0( stopped the sample collection at)]TJ
T*
0.005 Tc
0.0766 Tw
(the conclusion of the scheduled treatment, or treat-)Tj
T*
0.0159 Tc
0.1141 Tw
(ment was suspended prematurely because of pro-)Tj
T*
0.0049 Tc
0.0477 Tw
[(gression of the disease or of toxicity)64.9(,)-0.1( or when there)]TJ
T*
0.0499 Tw
(were factors that could alter the quality of the sam-)Tj
T*
0.047 Tw
[(ple such as a loss of weight >5%, infections, or ne-)]TJ
T*
0.0118 Tc
0.1182 Tw
[(ed for artificial nutrition. No other chemotherapy)65(,)]TJ
T*
0.005 Tc
0.1183 Tw
(immunotherapy or hormonal therapy was adminis-)Tj
T*
0.1113 Tw
[(tered nor radiotherapy)65(, or experimental medication)]TJ
T*
0.0315 Tw
(while the patients were in the present study; neither)Tj
T*
0.1145 Tw
[(did we use supplementary feeding \(enteral nor pa-)]TJ
T*
0.1094 Tw
[(renteral\). The response of the patients was evalua-)]TJ
T*
0.0053 Tc
0.1247 Tw
[(ted every 3 cycles of chemotherapy)65(, using clinical)]TJ
23.4616 56.7273 TD
0.0224 Tc
0.1076 Tw
(and radiographic techniques. The evaluation was)Tj
0 -1.1818 TD
0.005 Tc
0.0111 Tw
(according to the definitions of the WHO: )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 471.4977 670.9843 Tm
0 0 0 1 k
/GS1 gs
0.0049 Tc
0 Tw
(Complete)Tj
-16.9716 -1.1818 TD
0.0744 Tw
(Response \(CR\):)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 363.6277 657.9843 Tm
0 0 0 1 k
/GS1 gs
0.005 Tc
0.0744 Tw
(complete disappearance of the di-)Tj
-7.1652 -1.1818 TD
0.0597 Tw
(sease in two observation within an interval not less)Tj
T*
0.1232 Tw
(that 4 weeks; )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 350.4308 631.9843 Tm
0 0 0 1 k
/GS1 gs
0.0049 Tc
0.1232 Tw
(Partial Response \(PR\))Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 458.1434 631.9843 Tm
0 0 0 1 k
/GS1 gs
0.0049 Tc
0.1233 Tw
(: decrease of)Tj
-15.7575 -1.1818 TD
0.0661 Tw
[(50% or more in tumor size and of the lesions mea-)]TJ
T*
0.088 Tw
(sured in two observations within an interval of not)Tj
T*
0.0064 Tc
0.1236 Tw
(less that 4 weeks and, as well, without the appea-)Tj
T*
0.0049 Tc
0.0947 Tw
(rance of new lesions nor progression of any of the)Tj
T*
0 Tw
(existing lesions.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 284.8106 540.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Laboratory measur)17.7(ements)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 295.5539 514.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0523 Tw
(The measurements consisted of serum analysis of)Tj
-0.9767 -1.1818 TD
0 Tc
0.0517 Tw
[(27 dif)17.8(ferent amino acids. Blood sampling was befo-)]TJ
T*
0.0459 Tw
(re the start of the chemotherapy and at 72h after the)Tj
T*
0.0003 Tc
0.1247 Tw
(administration of the chemotherapy cycle. The AA)Tj
T*
0 Tc
0.0536 Tw
(measured were: aspartic acid, taurine, theronine, se-)Tj
T*
0.0947 Tw
[(rine, aspar)17.8(ginine, glutamic acid, glutamine, proline,)]TJ
T*
0.1191 Tw
(glycine, alanine, citrulline, aminobutyric acid, vali-)Tj
T*
0.069 Tw
(ne, cysteine, methionine, isoleucine, leucine, tyrosi-)Tj
T*
0.002 Tw
(ne, phenylalanine, tryptophan, ornithine, lysine, hys-)Tj
T*
0.0346 Tw
[(tidine, ar)17.8(ginine, hydroxyproline, 3-methyl hystidine,)]TJ
T*
0 Tw
(1 methyl hystidine.)Tj
0.9767 -1.1818 TD
-0.0001 Tc
0.0409 Tw
(The AAs were measured with a Beckman System)Tj
-0.9767 -1.1818 TD
0.0006 Tc
0.1244 Tw
(6300/7300 Amino Acid Analyzer \(Pickering Labo-)Tj
T*
0.02 Tc
0.1049 Tw
[(ratories\) according to the manufacturer)-36.9()55.2(s)0.1( instruc-)]TJ
T*
-0.0001 Tc
0.0971 Tw
(tions and protocols. Samples for analysis were pre-)Tj
T*
0 Tc
0.1093 Tw
(pared from 1 ml of blood collected into tubes con-)Tj
T*
0.0228 Tc
0.1022 Tw
(taining heparin. An aliquot \(20 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 437.1612 306.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 443.7479 306.9843 Tm
0 0 0 1 k
/GS1 gs
0.0228 Tc
0.1022 Tw
(L\) whole blood)Tj
-14.4488 -1.1818 TD
-0.0001 Tc
0.0394 Tw
(was transferred to a 400 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 395.391 293.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 401.7262 293.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0394 Tw
(L centrifuge tube and 200)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 284.8106 280.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 291.1458 280.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0195 Tw
[(L of a buf)17.8(fer solution \(pH 2.2 containing a mixture)]TJ
-0.5759 -1.1818 TD
0.025 Tc
0.1 Tw
(of hydrochloric acid and citric acid\), mixed tho-)Tj
T*
0 Tc
0.0696 Tw
(roughly and frozen and stored at 20C for batched)Tj
T*
0.023 Tc
0.102 Tw
(analysis to minimise methodological variation in)Tj
T*
0.0035 Tc
0.1215 Tw
[(measurement. Subsequently)64.9(, the samples were tha-)]TJ
T*
0 Tc
0.1231 Tw
[(wed and centrifuged at 13,000 rpm for 10 min. T)69.8(o)]TJ
T*
0.0702 Tw
(de-proteinise the sample, 200 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 420.1604 202.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 426.4956 202.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0702 Tw
(L of the supernatant)Tj
-12.8805 -1.1818 TD
0.1024 Tw
(was taken with a micropipette, transferred to a 400)Tj
T*
0.0197 Tw
(\(L centrifuge tube to which 20 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 422.9473 176.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 429.2825 176.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0197 Tw
(L of sulphosalicylic)Tj
-13.1338 -1.1818 TD
0.057 Tw
(acid was added and centrifuged at 13,000 rpm for 5)Tj
T*
0.0717 Tw
(min. Supernatant \(5 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 376.9844 150.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 383.3196 150.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0717 Tw
(L\) was mixed with 50% Li-A)Tj
-8.9554 -1.1818 TD
0.0672 Tw
[(\(Lithium citrate high performance AA analysis buf-)]TJ
T*
0.0001 Tw
(fer\) and passed through a 2 )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 406.9762 124.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 413.3114 124.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(L filter )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 284.8106 98.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Statistical analyses)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 295.5539 72.9843 Tm
0 0 0 1 k
/GS1 gs
0.0144 Tc
0.1105 Tw
(The comparisons of AA profile variation follo-)Tj
-0.9767 -1.1818 TD
0 Tc
0.0207 Tw
(wing the first chemotherapy cycle \(dichotomized in-)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.74 719.95 m
517.08 719.95 l
S
0 0 0 0 k
26.73 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 382.1097 734.168 Tm
0 0 0 1 k
/GS1 gs
0 Tc
-0.0001 Tw
(Oncologa, 2005; 28 \(7\):321-328)Tj
ET
0 0 0 0 k
493.07 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 507.0804 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(23)Tj
ET
Q
endstream
endobj
16 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
/F3 17 0 R
/F4 18 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
20 0 obj
<<
/Length 25065
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 26.7705 683.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0971 Tw
(dependent qualitative variable and dependent quan-)Tj
0 -1.1818 TD
0.0763 Tw
(titative variable with dependent samples\) were with)Tj
T*
0.0196 Tc
0.1054 Tw
[(the W)39.8(ilcoxon test. For the changes following the)]TJ
T*
0.0088 Tc
0.1162 Tw
(first cycle of treatment as a function of the tumor)Tj
T*
0 Tc
0.0902 Tw
(response, the dependent variable employed was de-)Tj
T*
0.062 Tw
[(fined as the percentage of variation \(%V\) relative)]TJ
T*
0.125 Tw
(to the baseline using the following formula: %V =)Tj
T*
-0.0005 Tc
0 Tw
(\(X)Tj
6.6 0 0 6.6 38.372 591.3343 Tm
0 Tc
(1)Tj
11 0 0 11 41.6721 592.9843 Tm
-0.0005 Tc
(-X)Tj
6.6 0 0 6.6 53.2736 591.3343 Tm
0 Tc
(b)Tj
11 0 0 11 56.5736 592.9843 Tm
-0.0001 Tc
0.0724 Tw
(\) / X)Tj
6.6 0 0 6.6 78.3248 591.3343 Tm
0 Tc
0 Tw
(b)Tj
11 0 0 11 81.6248 592.9843 Tm
0.0724 Tw
(; \(dichotomized qualitative independent)Tj
-4.9868 -1.1818 TD
0.0311 Tc
0.0939 Tw
(variable and the quantitative dependent variable)Tj
T*
0.0145 Tc
0.1105 Tw
(with independent samples\) and comparisons were)Tj
T*
0 Tc
0 Tw
(with the Mann-Whitney test. )Tj
T*
(Where:)Tj
T*
(X)Tj
6.6 0 0 6.6 34.7116 526.3342 Tm
(1)Tj
11 0 0 11 38.0117 527.9843 Tm
-0.0001 Tc
0.0001 Tw
(= AA value following the first cycle)Tj
-1.0219 -1.1818 TD
0 Tc
0 Tw
(X)Tj
6.6 0 0 6.6 34.7116 513.3343 Tm
(b)Tj
11 0 0 11 38.0117 514.9843 Tm
(= AA value at baseline)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 26.7705 475.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0002 Tc
0 Tw
(Results)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.5138 449.9843 Tm
0 0 0 1 k
/GS1 gs
0.0291 Tc
0.0958 Tw
(The characteristics of the patients were as fo-)Tj
-0.9767 -1.1818 TD
0 Tc
0.1155 Tw
(llows: the median age of the patients was 58 years)Tj
T*
0.0176 Tw
[(\(range 23-70\). The gender distribution was 48 males)]TJ
T*
0.011 Tc
0.1139 Tw
[(\(88%\) and 6 females \(12%\). T)34.9(umor sites were 27)]TJ
23.4616 24.8182 TD
0.0176 Tc
0.1074 Tw
(patients \(50%\) with epidermoid carcinoma of the)Tj
0 -1.1818 TD
0 Tc
0.0539 Tw
(head & neck, 24 patients \(44.4%\) lung cancer 17 of)Tj
T*
0.1223 Tw
[(whom \(70%\) with histology of microcytic carcino-)]TJ
T*
0.0615 Tw
[(ma and 7 patients \(30%\) with non-microcytic carci-)]TJ
T*
0.0013 Tc
0.1237 Tw
(noma, and 3 patients \(5.6%\) with malignant germ-)Tj
T*
0 Tc
0 Tw
[(cell testicular tumor)54.9(.)]TJ
0.9767 -1.1818 TD
0.0321 Tw
(A total of 254 cycles was administered and distri-)Tj
-0.9767 -1.1818 TD
0.0667 Tw
(buted as: 2 cycles to 1 patient \(1.9%\); 3 cycles to 3)Tj
T*
0.0322 Tw
(patients \(5.5%\); 4 cycles to 27 patients \(50%\); 5 cy-)Tj
T*
0.0221 Tc
0.1029 Tw
(cles to 3 patients \(5.5%\); 6 cycles to 20 patients)Tj
T*
0 Tc
0.0294 Tw
(\(37.1%\). A total of 50 patients \(93%\) received at le-)Tj
T*
0.0057 Tc
0.1193 Tw
(ast 4 cycles. There were 308 measurements made.)Tj
T*
0.0394 Tc
0.0856 Tw
(Apart from measuring the levels of each of the)Tj
T*
0 Tc
0.0045 Tw
(27AA at baseline \(1 or 2 days prior to chemotherapy)Tj
T*
0.0036 Tc
0.1214 Tw
(commencement\) these same parameters were mea-)Tj
T*
0 Tc
0.0232 Tw
(sured 72h after the administration of each of the cis-)Tj
T*
0 Tw
(platin cycles. )Tj
0.9767 -1.1818 TD
-0.0798 Tc
(We)Tj
1.3078 0 TD
( )Tj
0.2623 0 TD
0 Tc
0.0123 Tw
(established two groups according to the tumor)Tj
-2.5468 -1.1818 TD
0.0136 Tw
(response that occurred following the initiation of the)Tj
T*
0.0181 Tc
0 Tw
(chemotherapy: )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 356.9158 436.9843 Tm
0 0 0 1 k
/GS1 gs
0.018 Tc
0.1068 Tw
[(Gr)17.8(oup A:)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 409.1315 436.9843 Tm
0 0 0 1 k
/GS1 gs
0.018 Tc
0.107 Tw
(Patients with partial or)Tj
-11.2985 -1.1818 TD
0 Tc
0.0001 Tw
(complete response and )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 387.7813 423.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0001 Tw
[(Gr)17.7(oup B:)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 435.2539 423.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0001 Tw
(No responding pa-)Tj
-13.6733 -1.1818 TD
-0.0001 Tc
0.0941 Tw
[(tients. In Figures 1 and 2 are representations of the)]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.77 719.95 m
517.12 719.95 l
S
0 0 0 0 k
26.77 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 26.7705 734.168 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(M. Cobo-Dols y cols.)Tj
ET
0 0 0 0 k
26.77 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 26.7705 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(24)Tj
ET
0 0 0 0 k
26.77 404.16 490.35 -331.18 re
f
Q
BT
/TT2 1 Tf
9.6 0 0 9.6 223.5774 264.6499 Tm
0 0 0 1 k
/GS2 gs
-0.0159 Tc
0 Tw
(ciclo)Tj
0 9.6 -9.6 0 200.336 289.7032 Tm
0 Tc
(Prolina en sangre)Tj
9.6 0 0 9.6 204.3415 371.3677 Tm
(280)Tj
0 -1.8189 TD
(260)Tj
T*
(240)Tj
T*
(220)Tj
T*
(200)Tj
T*
(180)Tj
ET
0 0 0 1 K
0 J 0 j 1.2 w 3.864 M []0 d
1 i
222.233 287.336 m
224.879 287.336 l
344.106 287.411 m
344.106 283.985 l
324.168 287.411 m
324.168 283.985 l
304.23 287.411 m
304.23 283.985 l
284.291 287.411 m
284.291 283.985 l
264.107 287.411 m
264.107 283.985 l
244.169 287.411 m
244.169 283.985 l
224.476 287.411 m
224.476 283.985 l
224.476 374.744 119.63 -87.333 re
S
BT
11.077 0 0 10.2875 222.0148 274.6078 Tm
-0.0284 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
9.6 0 0 9.6 267.5804 382.9643 Tm
0 Tc
(Proline)Tj
ET
222.605 357.768 m
224.772 357.768 l
222.605 339.564 m
224.772 339.564 l
222.605 321.9 m
224.772 321.9 l
222.605 304.582 m
224.772 304.582 l
S
[1.2 1.2 ]0 d
224.622 319.122 m
243.605 370.633 l
263.892 312.38 l
284.179 301.879 l
303.815 329.157 l
324.102 338.105 l
344.748 351.65 l
S
[]0 d
224.187 319.992 m
243.605 301.227 l
264.545 304.303 l
283.745 310.392 l
304.032 340.963 l
323.232 335.277 l
344.748 338.322 l
S
0 0 0 0 k
0.6 w
241.512 369.938 m
241.512 371.139 242.485 372.113 243.687 372.113 c
244.888 372.113 245.861 371.139 245.861 369.938 c
245.861 368.737 244.888 367.763 243.687 367.763 c
242.485 367.763 241.512 368.737 241.512 369.938 c
b
261.799 311.903 m
261.799 313.104 262.773 314.078 263.974 314.078 c
265.175 314.078 266.149 313.104 266.149 311.903 c
266.149 310.702 265.175 309.728 263.974 309.728 c
262.773 309.728 261.799 310.702 261.799 311.903 c
b
241.512 301.433 m
241.512 302.634 242.485 303.608 243.687 303.608 c
244.888 303.608 245.861 302.634 245.861 301.433 c
245.861 300.232 244.888 299.258 243.687 299.258 c
242.485 299.258 241.512 300.232 241.512 301.433 c
b
261.582 304.292 m
261.582 305.493 262.555 306.466 263.757 306.466 c
264.957 306.466 265.931 305.493 265.931 304.292 c
265.931 303.09 264.957 302.117 263.757 302.117 c
262.555 302.117 261.582 303.09 261.582 304.292 c
b
281.652 310.381 m
281.652 311.582 282.625 312.555 283.826 312.555 c
285.027 312.555 286.001 311.582 286.001 310.381 c
286.001 309.18 285.027 308.206 283.826 308.206 c
282.625 308.206 281.652 309.18 281.652 310.381 c
b
281.652 301.868 m
281.652 303.069 282.625 304.043 283.826 304.043 c
285.027 304.043 286.001 303.069 286.001 301.868 c
286.001 300.667 285.027 299.693 283.826 299.693 c
282.625 299.693 281.652 300.667 281.652 301.868 c
b
301.721 340.486 m
301.721 341.687 302.695 342.66 303.896 342.66 c
305.097 342.66 306.071 341.687 306.071 340.486 c
306.071 339.284 305.097 338.311 303.896 338.311 c
302.695 338.311 301.721 339.284 301.721 340.486 c
b
301.721 328.928 m
301.721 330.129 302.695 331.103 303.896 331.103 c
305.097 331.103 306.071 330.129 306.071 328.928 c
306.071 327.727 305.097 326.754 303.896 326.754 c
302.695 326.754 301.721 327.727 301.721 328.928 c
b
321.139 338.746 m
321.139 339.947 322.113 340.921 323.314 340.921 c
324.515 340.921 325.489 339.947 325.489 338.746 c
325.489 337.545 324.515 336.571 323.314 336.571 c
322.113 336.571 321.139 337.545 321.139 338.746 c
b
322.009 334.614 m
322.009 335.815 322.982 336.789 324.184 336.789 c
325.384 336.789 326.358 335.815 326.358 334.614 c
326.358 333.413 325.384 332.439 324.184 332.439 c
322.982 332.439 322.009 333.413 322.009 334.614 c
b
341.644 351.608 m
341.644 352.809 342.617 353.783 343.819 353.783 c
345.02 353.783 345.993 352.809 345.993 351.608 c
345.993 350.407 345.02 349.433 343.819 349.433 c
342.617 349.433 341.644 350.407 341.644 351.608 c
b
341.644 338.311 m
341.644 339.512 342.617 340.486 343.819 340.486 c
345.02 340.486 345.993 339.512 345.993 338.311 c
345.993 337.11 345.02 336.136 343.819 336.136 c
342.617 336.136 341.644 337.11 341.644 338.311 c
b
BT
9.8101 0 0 10.5 259.3699 222.2299 Tm
0 0 0 1 k
(Asparragine)Tj
6.7269 0 0 7.2 313.8696 264.7702 Tm
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
0 0 0 0 k
300.585 266.48 m
300.585 267.681 301.559 268.655 302.76 268.655 c
303.961 268.655 304.935 267.681 304.935 266.48 c
304.935 265.279 303.961 264.305 302.76 264.305 c
301.559 264.305 300.585 265.279 300.585 266.48 c
b
300.585 252.304 m
300.585 253.505 301.559 254.479 302.76 254.479 c
303.961 254.479 304.935 253.505 304.935 252.304 c
304.935 251.103 303.961 250.13 302.76 250.13 c
301.559 250.13 300.585 251.103 300.585 252.304 c
b
1.2 w
300.585 255.804 m
311.19 255.804 l
S
[1.2 1.2 ]0 d
300.585 270.094 m
311.19 270.094 l
S
[]0 d
185.331 281.566 m
185.331 277.969 l
165.892 281.566 m
165.892 277.969 l
146.452 281.566 m
146.452 277.969 l
127.012 281.566 m
127.012 277.969 l
107.332 281.566 m
107.332 277.969 l
87.893 281.566 m
87.893 277.969 l
68.693 281.566 m
68.693 277.969 l
68.693 373.25 116.639 -91.684 re
S
BT
9.6 0 0 9.6 66.2925 267.8853 Tm
0 0 0 1 k
0.0067 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
4.349 11.6253 TD
0 Tc
(Alanine)Tj
0 9.6 -9.6 0 46.3484 291.1631 Tm
(Arginina en sangre)Tj
9.6 0 0 9.6 50.5981 368.0578 Tm
-0.0159 Tc
(120)Tj
0 -1.807 TD
(100)Tj
0.5403 -1.8069 TD
(80)Tj
T*
(60)Tj
T*
(40)Tj
T*
(20)Tj
ET
66.286 355.729 m
68.453 355.729 l
66.286 337.008 m
68.453 337.008 l
66.286 318.528 m
68.453 318.528 l
66.286 300.047 m
68.453 300.047 l
66.286 281.566 m
68.932 281.566 l
68.693 337.248 m
87.893 368.446 l
107.332 335.569 l
126.772 342.532 l
165.892 311.086 l
184.852 325.969 l
S
[1.2 1.2 ]0 d
68.693 340.374 m
75.167 339.646 l
79.492 338.447 l
86.214 338.207 l
107.572 323.812 l
119.57 324.052 l
120.529 323.332 l
127.731 323.572 l
162.774 307.249 l
185.092 291.886 l
S
BT
6.7269 0 0 7.2 154.7475 258.1699 Tm
0 Tc
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
[]0 d
141.463 249.204 m
152.068 249.204 l
S
[1.2 1.2 ]0 d
141.463 263.494 m
152.068 263.494 l
S
BT
9.6 0 0 9.6 67.3699 257.45 Tm
-0.0159 Tc
(ciclo)Tj
6.7269 0 0 7.2 467.0754 264.1561 Tm
0 Tc
(RC RP)Tj
T*
(EE PROG)Tj
ET
0 0 0 0 k
0.6 w []0 d
453.791 265.866 m
453.791 267.067 454.765 268.041 455.966 268.041 c
457.167 268.041 458.141 267.067 458.141 265.866 c
458.141 264.665 457.167 263.691 455.966 263.691 c
454.765 263.691 453.791 264.665 453.791 265.866 c
b
453.791 251.69 m
453.791 252.891 454.765 253.865 455.966 253.865 c
457.167 253.865 458.141 252.891 458.141 251.69 c
458.141 250.489 457.167 249.516 455.966 249.516 c
454.765 249.516 453.791 250.489 453.791 251.69 c
b
1.2 w
453.791 255.19 m
464.396 255.19 l
S
[1.2 1.2 ]0 d
453.791 269.48 m
464.396 269.48 l
S
BT
9.6 0 0 9.6 384.17 262.2499 Tm
0 0 0 1 k
(ciclo)Tj
ET
[]0 d
382.406 287.271 m
384.81 287.271 l
493.114 287.344 m
493.114 284.013 l
475.002 287.344 m
475.002 284.013 l
456.891 287.344 m
456.891 284.013 l
438.779 287.344 m
438.779 284.013 l
420.444 287.344 m
420.444 284.013 l
402.332 287.344 m
402.332 284.013 l
384.444 287.344 m
384.444 284.013 l
384.444 372.251 108.671 -84.907 re
S
BT
10.0622 0 0 10.0018 382.2078 274.8963 Tm
-0.0284 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
8.9692 0 0 9.6 415.1989 380.0304 Tm
0 Tc
(Methionine)Tj
ET
382.527 344.596 m
384.495 344.596 l
382.309 316.929 m
384.278 316.929 l
S
BT
0 9.6 -9.6 0 363.5039 287.1945 Tm
(Metionina en sangre)Tj
9.6 0 0 9.6 368.8613 368.0599 Tm
-0.0159 Tc
(50)Tj
0 -2.7604 TD
(40)Tj
T*
(30)Tj
T*
(20)Tj
ET
384.178 307.887 m
401.855 315.965 l
439.137 301.798 l
456.38 311.18 l
475.362 312.703 l
493.04 302.45 l
S
0 0 0 0 k
0.6 w
400.519 315.747 m
400.519 316.948 401.493 317.922 402.694 317.922 c
403.895 317.922 404.869 316.948 404.869 315.747 c
404.869 314.547 403.895 313.573 402.694 313.573 c
401.493 313.573 400.519 314.547 400.519 315.747 c
b
418.186 309.585 m
418.186 310.786 419.16 311.76 420.361 311.76 c
421.562 311.76 422.536 310.786 422.536 309.585 c
422.536 308.384 421.562 307.411 420.361 307.411 c
419.16 307.411 418.186 308.384 418.186 309.585 c
b
436.951 301.508 m
436.951 302.709 437.925 303.682 439.126 303.682 c
440.327 303.682 441.301 302.709 441.301 301.508 c
441.301 300.307 440.327 299.333 439.126 299.333 c
437.925 299.333 436.951 300.307 436.951 301.508 c
b
454.847 311.325 m
454.847 312.526 455.82 313.5 457.021 313.5 c
458.222 313.5 459.196 312.526 459.196 311.325 c
459.196 310.124 458.222 309.15 457.021 309.15 c
455.82 309.15 454.847 310.124 454.847 311.325 c
b
473.394 312.444 m
473.394 313.645 474.368 314.618 475.569 314.618 c
476.77 314.618 477.744 313.645 477.744 312.444 c
477.744 311.243 476.77 310.269 475.569 310.269 c
474.368 310.269 473.394 311.243 473.394 312.444 c
b
491.072 302.378 m
491.072 303.579 492.046 304.552 493.247 304.552 c
494.448 304.552 495.421 303.579 495.421 302.378 c
495.421 301.177 494.448 300.203 493.247 300.203 c
492.046 300.203 491.072 301.177 491.072 302.378 c
b
1.2 w [1.2 1.2 ]0 d
384.178 320.314 m
401.855 351.103 l
419.937 319.444 l
456.814 320.314 l
474.927 325.565 l
492.822 323.39 l
S
0.6 w []0 d
472.907 325.021 m
472.907 326.222 473.881 327.196 475.082 327.196 c
476.283 327.196 477.257 326.222 477.257 325.021 c
477.257 323.82 476.283 322.847 475.082 322.847 c
473.881 322.847 472.907 323.82 472.907 325.021 c
b
491.269 323.25 m
491.269 324.451 492.242 325.425 493.443 325.425 c
494.644 325.425 495.618 324.451 495.618 323.25 c
495.618 322.049 494.644 321.075 493.443 321.075 c
492.242 321.075 491.269 322.049 491.269 323.25 c
b
454.794 320.609 m
454.794 321.81 455.768 322.784 456.969 322.784 c
458.17 322.784 459.144 321.81 459.144 320.609 c
459.144 319.408 458.17 318.434 456.969 318.434 c
455.768 318.434 454.794 319.408 454.794 320.609 c
b
399.411 350.601 m
399.411 351.802 400.385 352.776 401.586 352.776 c
402.787 352.776 403.761 351.802 403.761 350.601 c
403.761 349.4 402.787 348.426 401.586 348.426 c
400.385 348.426 399.411 349.4 399.411 350.601 c
b
417.699 319.305 m
417.699 320.505 418.673 321.479 419.874 321.479 c
421.075 321.479 422.049 320.505 422.049 319.305 c
422.049 318.103 421.075 317.13 419.874 317.13 c
418.673 317.13 417.699 318.103 417.699 319.305 c
b
436.247 320.174 m
436.247 321.375 437.221 322.349 438.422 322.349 c
439.623 322.349 440.596 321.375 440.596 320.174 c
440.596 318.973 439.623 318 438.422 318 c
437.221 318 436.247 318.973 436.247 320.174 c
b
BT
9.6 0 0 9.6 67.3967 98.4335 Tm
0 0 0 1 k
(ciclo)Tj
ET
1.2 w
189.856 121.245 m
189.856 117.53 l
169.88 121.245 m
169.88 117.53 l
149.903 121.245 m
149.903 117.53 l
129.927 121.245 m
129.927 117.53 l
109.705 121.245 m
109.705 117.53 l
89.729 121.245 m
89.729 117.53 l
69.999 121.245 m
69.999 117.53 l
69.999 215.929 119.857 -94.685 re
S
BT
9.6 0 0 9.6 68.711 108.0335 Tm
0.0169 Tc
[(0 )-15.8(1 2 3 4 5 6)]TJ
9.8101 0 0 10.5 91.7979 224.7635 Tm
0 Tc
(Phenylalanine)Tj
0 9.6 -9.6 0 50.7987 122.764 Tm
(Fenilalanina sangre)Tj
9.6 0 0 9.6 51.0532 211.2499 Tm
-0.0159 Tc
(100)Tj
0.5403 -2.4405 TD
(90)Tj
T*
(80)Tj
T*
(70)Tj
T*
(60)Tj
ET
68.676 191.934 m
70.644 191.934 l
68.297 168.423 m
70.265 168.423 l
68.51 121.286 m
70.478 121.286 l
68.422 145.219 m
70.391 145.219 l
S
[1.2 1.2 ]0 d
70.288 128.239 m
90.295 206.652 l
110.22 143.808 l
129.824 168.979 l
149.911 163.252 l
189.856 165.671 l
S
[]0 d
70.046 147.843 m
89.73 177.046 l
109.737 151.069 l
150.072 152.844 l
169.999 147.116 l
189.856 129.611 l
S
0 0 0 0 k
0.6 w
107.993 144.195 m
107.993 145.396 108.966 146.37 110.167 146.37 c
111.368 146.37 112.342 145.396 112.342 144.195 c
112.342 142.994 111.368 142.021 110.167 142.021 c
108.966 142.021 107.993 142.994 107.993 144.195 c
b
127.806 152.365 m
127.806 153.566 128.78 154.54 129.981 154.54 c
131.182 154.54 132.156 153.566 132.156 152.365 c
132.156 151.164 131.182 150.19 129.981 150.19 c
128.78 150.19 127.806 151.164 127.806 152.365 c
b
147.491 152.607 m
147.491 153.808 148.464 154.781 149.665 154.781 c
150.866 154.781 151.84 153.808 151.84 152.607 c
151.84 151.406 150.866 150.432 149.665 150.432 c
148.464 150.432 147.491 151.406 147.491 152.607 c
b
147.813 163.094 m
147.813 164.295 148.787 165.269 149.988 165.269 c
151.189 165.269 152.163 164.295 152.163 163.094 c
152.163 161.893 151.189 160.92 149.988 160.92 c
148.787 160.92 147.813 161.893 147.813 163.094 c
b
127.806 168.5 m
127.806 169.701 128.78 170.674 129.981 170.674 c
131.182 170.674 132.156 169.701 132.156 168.5 c
132.156 167.299 131.182 166.325 129.981 166.325 c
128.78 166.325 127.806 167.299 127.806 168.5 c
b
167.895 164.304 m
167.895 165.505 168.868 166.479 170.069 166.479 c
171.27 166.479 172.244 165.505 172.244 164.304 c
172.244 163.103 171.27 162.129 170.069 162.129 c
168.868 162.129 167.895 163.103 167.895 164.304 c
b
167.895 146.96 m
167.895 148.161 168.868 149.135 170.069 149.135 c
171.27 149.135 172.244 148.161 172.244 146.96 c
172.244 145.759 171.27 144.785 170.069 144.785 c
168.868 144.785 167.895 145.759 167.895 146.96 c
b
187.82 165.354 m
187.82 166.555 188.794 167.528 189.995 167.528 c
191.196 167.528 192.17 166.555 192.17 165.354 c
192.17 164.152 191.196 163.179 189.995 163.179 c
188.794 163.179 187.82 164.152 187.82 165.354 c
b
87.636 176.967 m
87.636 178.168 88.609 179.141 89.81 179.141 c
91.011 179.141 91.985 178.168 91.985 176.967 c
91.985 175.766 91.011 174.792 89.81 174.792 c
88.609 174.792 87.636 175.766 87.636 176.967 c
b
88.363 206.166 m
88.363 207.368 89.337 208.341 90.538 208.341 c
91.739 208.341 92.713 207.368 92.713 206.166 c
92.713 204.965 91.739 203.992 90.538 203.992 c
89.337 203.992 88.363 204.965 88.363 206.166 c
b
108.047 151.076 m
108.047 152.277 109.021 153.251 110.222 153.251 c
111.423 153.251 112.396 152.277 112.396 151.076 c
112.396 149.875 111.423 148.901 110.222 148.901 c
109.021 148.901 108.047 149.875 108.047 151.076 c
b
BT
6.7269 0 0 7.2 161.4696 98.5702 Tm
0 0 0 1 k
0 Tc
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
0 0 0 0 k
148.185 100.28 m
148.185 101.481 149.159 102.455 150.36 102.455 c
151.561 102.455 152.535 101.481 152.535 100.28 c
152.535 99.079 151.561 98.105 150.36 98.105 c
149.159 98.105 148.185 99.079 148.185 100.28 c
b
148.185 86.104 m
148.185 87.305 149.159 88.279 150.36 88.279 c
151.561 88.279 152.535 87.305 152.535 86.104 c
152.535 84.903 151.561 83.93 150.36 83.93 c
149.159 83.93 148.185 84.903 148.185 86.104 c
b
1.2 w
148.185 89.604 m
158.79 89.604 l
S
[1.2 1.2 ]0 d
148.185 103.894 m
158.79 103.894 l
S
[]0 d
227.608 191.256 m
229.623 191.256 l
227.763 167.717 m
229.778 167.717 l
268.172 144.797 m
270.187 144.797 l
268.172 120.782 m
270.187 120.782 l
346.064 120.796 m
346.064 117.199 l
326.624 120.796 m
326.624 117.199 l
307.185 120.796 m
307.185 117.199 l
287.745 120.796 m
287.745 117.199 l
268.065 120.796 m
268.065 117.199 l
248.625 120.796 m
248.625 117.199 l
229.425 120.796 m
229.425 117.199 l
229.425 212.48 116.639 -91.684 re
S
BT
9.6 0 0 9.6 227.0253 107.1143 Tm
0 0 0 1 k
0.0067 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
0.242 -1.1899 TD
-0.0159 Tc
(ciclo)Tj
ET
[1.2 1.2 ]0 d
229.639 136.204 m
249.09 196.826 l
268.542 145.301 l
288.246 170.041 l
307.446 130.886 l
327.15 172.559 l
346.35 152.1 l
S
[]0 d
229.387 145.301 m
248.587 141.997 l
268.29 144.797 l
287.994 141.745 l
326.898 156.663 l
345.846 135.701 l
S
BT
0 9.6 -9.6 0 213.2569 126.7709 Tm
0 Tc
(Asparragina sangre)Tj
9.6 0 0 9.6 215.8657 210.3612 Tm
-0.0159 Tc
(70)Tj
0 -2.3989 TD
(60)Tj
T*
(50)Tj
T*
(40)Tj
T*
(30)Tj
ET
227.152 145.359 m
229.167 145.359 l
227.152 120.731 m
229.167 120.731 l
S
BT
6.7269 0 0 7.2 315.4458 97.0106 Tm
0 Tc
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
302.161 88.045 m
312.766 88.045 l
S
[1.2 1.2 ]0 d
302.161 102.334 m
312.766 102.334 l
S
BT
8.4772 0 0 9.8331 388.4869 106.7646 Tm
0.0067 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
ET
0 0 0 0 k
0.6 w []0 d
423.526 166.439 m
423.526 167.64 424.499 168.613 425.7 168.613 c
426.901 168.613 427.875 167.64 427.875 166.439 c
427.875 165.237 426.901 164.264 425.7 164.264 c
424.499 164.264 423.526 165.237 423.526 166.439 c
b
405.95 206.47 m
405.95 207.671 406.924 208.645 408.125 208.645 c
409.326 208.645 410.3 207.671 410.3 206.47 c
410.3 205.269 409.326 204.296 408.125 204.296 c
406.924 204.296 405.95 205.269 405.95 206.47 c
b
439.603 176.594 m
439.603 177.795 440.577 178.769 441.777 178.769 c
442.979 178.769 443.952 177.795 443.952 176.594 c
443.952 175.393 442.979 174.42 441.777 174.42 c
440.577 174.42 439.603 175.393 439.603 176.594 c
b
456.869 169.857 m
456.869 171.058 457.842 172.031 459.044 172.031 c
460.245 172.031 461.218 171.058 461.218 169.857 c
461.218 168.656 460.245 167.682 459.044 167.682 c
457.842 167.682 456.869 168.656 456.869 169.857 c
b
457.101 160.257 m
457.101 161.458 458.074 162.431 459.276 162.431 c
460.477 162.431 461.45 161.458 461.45 160.257 c
461.45 159.056 460.477 158.082 459.276 158.082 c
458.074 158.082 457.101 159.056 457.101 160.257 c
b
422.885 157.24 m
422.885 158.441 423.859 159.414 425.06 159.414 c
426.261 159.414 427.235 158.441 427.235 157.24 c
427.235 156.038 426.261 155.065 425.06 155.065 c
423.859 155.065 422.885 156.038 422.885 157.24 c
b
473.888 196.167 m
473.888 197.368 474.862 198.341 476.063 198.341 c
477.264 198.341 478.238 197.368 478.238 196.167 c
478.238 194.966 477.264 193.992 476.063 193.992 c
474.862 193.992 473.888 194.966 473.888 196.167 c
b
491.541 195.316 m
491.541 196.517 492.515 197.49 493.716 197.49 c
494.917 197.49 495.891 196.517 495.891 195.316 c
495.891 194.115 494.917 193.141 493.716 193.141 c
492.515 193.141 491.541 194.115 491.541 195.316 c
b
474.036 149.897 m
474.036 151.099 475.009 152.072 476.211 152.072 c
477.412 152.072 478.385 151.099 478.385 149.897 c
478.385 148.696 477.412 147.723 476.211 147.723 c
475.009 147.723 474.036 148.696 474.036 149.897 c
b
439.61 146.494 m
439.61 147.694 440.584 148.668 441.784 148.668 c
442.986 148.668 443.959 147.694 443.959 146.494 c
443.959 145.293 442.986 144.319 441.784 144.319 c
440.584 144.319 439.61 145.293 439.61 146.494 c
b
405.641 178.057 m
405.641 179.258 406.615 180.232 407.816 180.232 c
409.017 180.232 409.991 179.258 409.991 178.057 c
409.991 176.856 409.017 175.882 407.816 175.882 c
406.615 175.882 405.641 176.856 405.641 178.057 c
b
BT
9.6 0 0 9.6 389.9991 94.4909 Tm
0 0 0 1 k
-0.0159 Tc
(ciclo)Tj
ET
1.2 w
388.166 189.643 m
390.409 189.643 l
388.166 166.188 m
390.409 166.188 l
388.166 142.649 m
390.409 142.649 l
S
[1.2 1.2 ]0 d
390.674 148.69 m
408.017 206.522 l
424.889 165.802 l
441.923 176.175 l
459.112 169.051 l
476.378 195.298 l
493.411 194.988 l
S
[]0 d
493.411 128.485 m
476.223 149.387 l
459.034 160.379 l
442 146.524 l
425.051 156.975 l
407.707 177.8 l
390.409 169.438 l
388.166 120.2 m
390.409 120.2 l
493.603 120.178 m
493.603 116.494 l
476.437 120.178 m
476.437 116.494 l
459.271 120.178 m
459.271 116.494 l
442.105 120.178 m
442.105 116.494 l
424.727 120.178 m
424.727 116.494 l
407.561 120.178 m
407.561 116.494 l
390.606 120.178 m
390.606 116.494 l
390.606 214.088 102.997 -93.91 re
S
0 0 0 0 k
0.6 w
491.303 128.396 m
491.303 129.596 492.276 130.57 493.478 130.57 c
494.678 130.57 495.652 129.596 495.652 128.396 c
495.652 127.194 494.678 126.221 493.478 126.221 c
492.276 126.221 491.303 127.194 491.303 128.396 c
b
BT
9.6 0 0 9.6 371.044 209.3946 Tm
0 0 0 1 k
(180)Tj
0 -2.3639 TD
(160)Tj
T*
(140)Tj
T*
(120)Tj
T*
(100)Tj
9.8101 0 0 10.5 421.5607 222.4069 Tm
0 Tc
(Leucine)Tj
6.7269 0 0 7.2 462.0696 95.5699 Tm
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
0 0 0 0 k
448.785 97.28 m
448.785 98.481 449.759 99.454 450.96 99.454 c
452.161 99.454 453.135 98.481 453.135 97.28 c
453.135 96.079 452.161 95.105 450.96 95.105 c
449.759 95.105 448.785 96.079 448.785 97.28 c
b
448.785 83.104 m
448.785 84.305 449.759 85.279 450.96 85.279 c
452.161 85.279 453.135 84.305 453.135 83.104 c
453.135 81.903 452.161 80.929 450.96 80.929 c
449.759 80.929 448.785 81.903 448.785 83.104 c
b
1.2 w
448.785 86.604 m
459.39 86.604 l
S
[1.2 1.2 ]0 d
448.785 100.894 m
459.39 100.894 l
S
BT
0 9.6 -9.6 0 367.2448 136.2645 Tm
0 0 0 1 k
(Leucina sangre)Tj
ET
q
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 67 490.35 -10.35 re
f
BT
/F1 1 Tf
9 0 0 9 95.5146 60.8455 Tm
0 0 0 1 k
(Figure 1. Variation in AA concentration following chemotherapy according to tumor response \(I\).)Tj
ET
Q
endstream
endobj
21 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
/TT2 22 0 R
>>
/ExtGState <<
/GS1 8 0 R
/GS2 23 0 R
>>
>>
endobj
25 0 obj
<<
/Length 31616
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.73 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 27.0029 280.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0381 Tw
(variations in the profile of most representatives AA,)Tj
-0.0245 -1.1818 TD
0.0108 Tc
0.1142 Tw
(segregated with respect to tumor response to che-)Tj
T*
0 Tc
0 Tw
[(motherapy)65(. )]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 26.7332 228.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Analyses of changes in the AA following the first)Tj
0 -1.1818 TD
(cycle of chemotherapy)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 37.4765 189.9843 Tm
0 0 0 1 k
/GS1 gs
0.0099 Tc
0.0584 Tw
(The increase in the profile of serum AA eviden-)Tj
-0.9767 -1.1818 TD
0.0118 Tc
0.1232 Tw
(ced in the overall group of the patients following)Tj
T*
0.0311 Tc
0.1039 Tw
(the first cycle of chemotherapy was much more)Tj
T*
0.0145 Tc
0.1205 Tw
(evident in the responders than in the non-respon-)Tj
T*
0.0238 Tc
0.1111 Tw
(ders. For example, in patients who were respon-)Tj
T*
0.0099 Tc
0.1067 Tw
[(ders, the variation in the levels following the first)]TJ
T*
0.0347 Tw
[(cycle were statistically significant in 20 AA: alani-)]TJ
T*
0.0134 Tc
0.1216 Tw
[(ne, ar)17.8(ginine, asparagine, citrulline, phenylalanine,)]TJ
T*
0.0169 Tc
0.1181 Tw
(glycine, glutamine, hystidine, isoleucine, leucine,)Tj
T*
0.0119 Tc
0.1231 Tw
(lysine, methionine, ornitine, proline, serine, tauri-)Tj
T*
0.01 Tc
0.0667 Tw
(ne, tyrosine, threonine, tryptophan and valine. Ho-)Tj
23.4861 20.0909 TD
0.0235 Tc
0.1114 Tw
[(wever)39.8(, in the patients who were non-responders,)]TJ
-0.0245 -1.1818 TD
0.0099 Tc
0.1207 Tw
[(this dif)17.7(ference was only significant in tryptophan,)]TJ
T*
0.0176 Tc
0.1174 Tw
(threonine, tyrosine, glutamine, phenylalanine and)Tj
T*
0.0099 Tc
0 Tw
[(citrulline \(T)69.7(able I\). )]TJ
0.9767 -1.1818 TD
0 Tc
0.0011 Tw
(These data were obtained taking into account both)Tj
-0.9767 -1.1818 TD
-0.0001 Tc
0.0757 Tw
[(sub-groups of patients separately)64.9(. T)69.7(o)-0.1( compare these)]TJ
T*
0 Tc
0.0497 Tw
(data of both sub-groups, the variable percentage of)Tj
T*
0.0318 Tc
0.0931 Tw
(increment \(%)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
11 0 0 11 354.8161 189.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 361.8989 189.9843 Tm
0 0 0 1 k
/GS1 gs
0.0318 Tc
0.0932 Tw
(\) was calculated for each amino)Tj
-7.008 -1.1818 TD
0 Tc
0.0075 Tw
(acid. The increment in the level of the AA following)Tj
T*
0.0016 Tc
0.1234 Tw
(the first cycle of chemotherapy with respect to the)Tj
T*
0 Tc
0.0643 Tw
(baseline concentrations \(measured as percentage in-)Tj
T*
0.0203 Tc
0.1047 Tw
(crement\) was significantly greater in the patients)Tj
T*
0.0119 Tc
0.1131 Tw
(who responded to the therapy than those who did)Tj
T*
0 Tc
0.0595 Tw
(not in relation to 17 of the amino acids: alanine, ar-)Tj
T*
0.1185 Tw
[(ginine, aspar)17.8(ginine, citrulline, phenylalanine, glyci-)]TJ
T*
0.0034 Tc
0.1216 Tw
[(ne, hystidine, isoleucine, leucine, lysine, methioni-)]TJ
T*
0 Tc
0.1084 Tw
(ne, ornitine, proline, serine, tyrosine, theronine and)Tj
T*
-0.0001 Tc
0.0001 Tw
[(valine \(T)69.7(able II\). )]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.74 719.95 m
517.08 719.95 l
S
0 0 0 0 k
26.73 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 382.1097 734.168 Tm
0 0 0 1 k
/GS1 gs
0 Tc
-0.0001 Tw
(Oncologa, 2005; 28 \(7\):321-328)Tj
ET
0 0 0 0 k
493.07 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 507.0804 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(25)Tj
ET
0 0 0 0 k
26.73 691.61 490.35 -346.88 re
f
Q
BT
/TT2 1 Tf
9.44 0 0 9.44 64.6849 542.2081 Tm
0 0 0 1 k
/GS2 gs
-0.0159 Tc
0 Tw
(ciclo)Tj
0 9.44 -9.44 0 39.0197 584.8153 Tm
0 Tc
(Lisina en sangre)Tj
9.44 0 0 9.44 44.9171 669.353 Tm
(280)Tj
0 -1.6016 TD
(260)Tj
T*
(240)Tj
T*
(220)Tj
T*
(200)Tj
T*
(180)Tj
T*
(160)Tj
T*
(140)Tj
ET
0 0 0 1 K
0 J 0 j 1.18 w 3.864 M []0 d
1 i
187.883 566.843 m
187.883 562.768 l
167.899 566.843 m
167.899 562.768 l
147.915 566.843 m
147.915 562.768 l
127.931 566.843 m
127.931 562.768 l
107.7 566.843 m
107.7 562.768 l
87.716 566.843 m
87.716 562.768 l
67.978 566.843 m
67.978 562.768 l
67.978 670.71 119.905 -103.867 re
S
BT
8.5657 0 0 9.44 65.5111 553.8513 Tm
0.0598 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
9.44 0 0 9.44 110.696 678.5635 Tm
0 Tc
(L)Tj
0.5192 0 TD
(ysine)Tj
ET
64.685 656.55 m
67.635 656.55 l
64.685 641.21 m
67.34 641.21 l
64.685 627.05 m
67.635 627.05 l
64.685 612.005 m
67.635 612.005 l
64.685 596.665 m
67.34 596.665 l
64.685 581.915 m
67.635 581.915 l
64.685 566.87 m
67.635 566.87 l
S
[1.18 1.18 ]0 d
67.93 582.8 m
86.81 640.915 l
107.165 613.775 l
127.225 637.08 l
146.99 617.61 l
167.935 663.925 l
188.29 634.13 l
S
0 0 0 0 k
0.59 w []0 d
85.179 640.136 m
85.179 641.317 86.137 642.275 87.318 642.275 c
88.499 642.275 89.456 641.317 89.456 640.136 c
89.456 638.955 88.499 637.998 87.318 637.998 c
86.137 637.998 85.179 638.955 85.179 640.136 c
b
105.033 613.899 m
105.033 615.08 105.99 616.037 107.171 616.037 c
108.352 616.037 109.31 615.08 109.31 613.899 c
109.31 612.717 108.352 611.76 107.171 611.76 c
105.99 611.76 105.033 612.717 105.033 613.899 c
b
125.388 636.614 m
125.388 637.795 126.345 638.752 127.526 638.752 c
128.707 638.752 129.665 637.795 129.665 636.614 c
129.665 635.432 128.707 634.475 127.526 634.475 c
126.345 634.475 125.388 635.432 125.388 636.614 c
b
145.448 617.242 m
145.448 618.423 146.405 619.38 147.586 619.38 c
148.767 619.38 149.725 618.423 149.725 617.242 c
149.725 616.061 148.767 615.103 147.586 615.103 c
146.405 615.103 145.448 616.061 145.448 617.242 c
b
165.803 662.869 m
165.803 664.05 166.76 665.007 167.941 665.007 c
169.122 665.007 170.08 664.05 170.08 662.869 c
170.08 661.688 169.122 660.73 167.941 660.73 c
166.76 660.73 165.803 661.688 165.803 662.869 c
b
185.863 633.664 m
185.863 634.845 186.82 635.802 188.001 635.802 c
189.182 635.802 190.14 634.845 190.14 633.664 c
190.14 632.483 189.182 631.525 188.001 631.525 c
186.82 631.525 185.863 632.483 185.863 633.664 c
b
1.18 w
67.34 603.155 m
87.105 611.415 l
107.165 606.105 l
127.815 595.78 l
146.99 583.98 l
167.935 645.635 l
187.995 617.315 l
S
0.59 w
84.973 610.949 m
84.973 612.13 85.93 613.087 87.111 613.087 c
88.292 613.087 89.25 612.13 89.25 610.949 c
89.25 609.767 88.292 608.81 87.111 608.81 c
85.93 608.81 84.973 609.767 84.973 610.949 c
b
105.033 606.229 m
105.033 607.41 105.99 608.367 107.171 608.367 c
108.352 608.367 109.31 607.41 109.31 606.229 c
109.31 605.047 108.352 604.09 107.171 604.09 c
105.99 604.09 105.033 605.047 105.033 606.229 c
b
125.093 595.314 m
125.093 596.495 126.05 597.452 127.231 597.452 c
128.412 597.452 129.37 596.495 129.37 595.314 c
129.37 594.132 128.412 593.175 127.231 593.175 c
126.05 593.175 125.093 594.132 125.093 595.314 c
b
144.858 583.514 m
144.858 584.695 145.815 585.652 146.996 585.652 c
148.177 585.652 149.135 584.695 149.135 583.514 c
149.135 582.332 148.177 581.375 146.996 581.375 c
145.815 581.375 144.858 582.332 144.858 583.514 c
b
166.098 645.464 m
166.098 646.645 167.055 647.602 168.236 647.602 c
169.417 647.602 170.375 646.645 170.375 645.464 c
170.375 644.282 169.417 643.325 168.236 643.325 c
167.055 643.325 166.098 644.282 166.098 645.464 c
b
185.863 615.964 m
185.863 617.145 186.82 618.102 188.001 618.102 c
189.182 618.102 190.14 617.145 190.14 615.964 c
190.14 614.783 189.182 613.825 188.001 613.825 c
186.82 613.825 185.863 614.783 185.863 615.964 c
b
1.18 w
348.56 568.27 m
348.56 564.203 l
328.781 568.27 m
328.781 564.203 l
309.003 568.27 m
309.003 564.203 l
289.224 568.27 m
289.224 564.203 l
269.201 568.27 m
269.201 564.203 l
249.423 568.27 m
249.423 564.203 l
229.888 568.27 m
229.888 564.203 l
229.888 671.934 118.672 -103.664 re
S
BT
8.4942 0 0 9.44 227.4462 555.2892 Tm
0 0 0 1 k
0.0627 Tc
[(0 )-15.8(1 2 3 4 5 6)]TJ
9.44 0 0 9.44 207.7582 666.7672 Tm
0 Tc
(380)Tj
0 -1.3596 TD
(360)Tj
T*
(340)Tj
T*
(320)Tj
T*
(300)Tj
T*
(280)Tj
T*
(260)Tj
T*
(240)Tj
T*
(220)Tj
ET
226.695 657.935 m
229.795 657.935 l
226.695 645.093 m
229.795 645.093 l
226.695 632.332 m
229.795 632.332 l
226.695 619.189 m
229.795 619.189 l
226.695 605.824 m
229.795 605.824 l
226.695 593.063 m
229.795 593.063 l
226.695 580.523 m
229.795 580.523 l
229.795 568.366 m
226.695 568.366 l
S
BT
9.44 0 0 9.44 277.3078 679.2914 Tm
(Glysine)Tj
0 9.44 -9.44 0 204.4182 583.6182 Tm
(Glisina en sangre)Tj
9.44 0 0 9.44 230.5189 541.7152 Tm
-0.0159 Tc
(ciclo)Tj
6.6148 0 0 7.08 318.6256 541.2434 Tm
0 Tc
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
0 0 0 0 k
0.59 w
305.562 541.745 m
305.562 542.926 306.52 543.883 307.701 543.883 c
308.882 543.883 309.839 542.926 309.839 541.745 c
309.839 540.564 308.882 539.607 307.701 539.607 c
306.52 539.607 305.562 540.564 305.562 541.745 c
b
305.562 527.805 m
305.562 528.987 306.52 529.944 307.701 529.944 c
308.882 529.944 309.839 528.987 309.839 527.805 c
309.839 526.624 308.882 525.667 307.701 525.667 c
306.52 525.667 305.562 526.624 305.562 527.805 c
b
1.18 w
305.562 532.427 m
315.991 532.427 l
S
[1.18 1.18 ]0 d
305.562 546.478 m
315.991 546.478 l
S
[]0 d
229.795 583.925 m
248.977 584.528 l
263.32 590.038 276.611 596.834 288.85 604.918 c
308.636 639.659 l
329.328 608.541 l
348.899 593.969 l
S
0.59 w
246.654 584.577 m
246.654 585.758 247.612 586.716 248.793 586.716 c
249.974 586.716 250.932 585.758 250.932 584.577 c
250.932 583.396 249.974 582.439 248.793 582.439 c
247.612 582.439 246.654 583.396 246.654 584.577 c
b
286.528 604.665 m
286.528 605.846 287.485 606.804 288.666 606.804 c
289.847 606.804 290.805 605.846 290.805 604.665 c
290.805 603.484 289.847 602.527 288.666 602.527 c
287.485 602.527 286.528 603.484 286.528 604.665 c
b
306.314 638.722 m
306.314 639.903 307.271 640.86 308.452 640.86 c
309.633 640.86 310.59 639.903 310.59 638.722 c
310.59 637.54 309.633 636.583 308.452 636.583 c
307.271 636.583 306.314 637.54 306.314 638.722 c
b
327.005 608.288 m
327.005 609.469 327.963 610.427 329.144 610.427 c
330.325 610.427 331.282 609.469 331.282 608.288 c
331.282 607.107 330.325 606.15 329.144 606.15 c
327.963 606.15 327.005 607.107 327.005 608.288 c
b
1.18 w [1.18 1.18 ]0 d
229.795 600.309 m
248.373 660.652 l
268.159 582.717 l
288.85 610.131 l
308.636 594.572 l
329.931 617.981 l
348.899 604.918 l
S
0.59 w []0 d
266.44 583.068 m
266.44 584.249 267.398 585.206 268.579 585.206 c
269.76 585.206 270.717 584.249 270.717 583.068 c
270.717 581.887 269.76 580.929 268.579 580.929 c
267.398 580.929 266.44 581.887 266.44 583.068 c
b
246.272 658.89 m
246.272 660.071 247.229 661.028 248.41 661.028 c
249.591 661.028 250.549 660.071 250.549 658.89 c
250.549 657.709 249.591 656.751 248.41 656.751 c
247.229 656.751 246.272 657.709 246.272 658.89 c
b
306.917 594.018 m
306.917 595.198 307.875 596.156 309.056 596.156 c
310.237 596.156 311.194 595.198 311.194 594.018 c
311.194 592.836 310.237 591.879 309.056 591.879 c
307.875 591.879 306.917 592.836 306.917 594.018 c
b
327.307 617.124 m
327.307 618.305 328.264 619.263 329.445 619.263 c
330.627 619.263 331.584 618.305 331.584 617.124 c
331.584 615.943 330.627 614.986 329.445 614.986 c
328.264 614.986 327.307 615.943 327.307 617.124 c
b
286.528 610.402 m
286.528 611.583 287.485 612.54 288.666 612.54 c
289.847 612.54 290.805 611.583 290.805 610.402 c
290.805 609.22 289.847 608.263 288.666 608.263 c
287.485 608.263 286.528 609.22 286.528 610.402 c
b
346.791 604.061 m
346.791 605.242 347.748 606.2 348.93 606.2 c
350.11 606.2 351.068 605.242 351.068 604.061 c
351.068 602.88 350.11 601.923 348.93 601.923 c
347.748 601.923 346.791 602.88 346.791 604.061 c
b
347.181 593.414 m
347.181 594.595 348.138 595.552 349.319 595.552 c
350.5 595.552 351.458 594.595 351.458 593.414 c
351.458 592.233 350.5 591.275 349.319 591.275 c
348.138 591.275 347.181 592.233 347.181 593.414 c
b
266.742 592.81 m
266.742 593.991 267.7 594.948 268.881 594.948 c
270.062 594.948 271.019 593.991 271.019 592.81 c
271.019 591.629 270.062 590.671 268.881 590.671 c
267.7 590.671 266.742 591.629 266.742 592.81 c
b
BT
6.6148 0 0 7.08 158.6913 541.7363 Tm
0 0 0 1 k
(RC RP)Tj
T*
(EE PROG)Tj
ET
0 0 0 0 k
145.628 542.238 m
145.628 543.419 146.586 544.376 147.767 544.376 c
148.948 544.376 149.905 543.419 149.905 542.238 c
149.905 541.056 148.948 540.099 147.767 540.099 c
146.586 540.099 145.628 541.056 145.628 542.238 c
b
145.628 528.298 m
145.628 529.479 146.586 530.437 147.767 530.437 c
148.948 530.437 149.905 529.479 149.905 528.298 c
149.905 527.117 148.948 526.16 147.767 526.16 c
146.586 526.16 145.628 527.117 145.628 528.298 c
b
1.18 w
145.628 532.92 m
156.057 532.92 l
S
[1.18 1.18 ]0 d
145.628 546.971 m
156.057 546.971 l
S
BT
6.6148 0 0 7.08 162.6523 366.506 Tm
0 0 0 1 k
(RC RP)Tj
T*
(EE PROG)Tj
ET
0 0 0 0 k
0.59 w []0 d
149.589 367.008 m
149.589 368.189 150.547 369.146 151.728 369.146 c
152.909 369.146 153.866 368.189 153.866 367.008 c
153.866 365.827 152.909 364.869 151.728 364.869 c
150.547 364.869 149.589 365.827 149.589 367.008 c
b
149.589 353.068 m
149.589 354.249 150.547 355.207 151.728 355.207 c
152.909 355.207 153.866 354.249 153.866 353.068 c
153.866 351.887 152.909 350.93 151.728 350.93 c
150.547 350.93 149.589 351.887 149.589 353.068 c
b
1.18 w
149.589 357.69 m
160.017 357.69 l
S
[1.18 1.18 ]0 d
149.589 371.741 m
160.017 371.741 l
S
BT
6.6148 0 0 7.08 475.5054 541.7363 Tm
0 0 0 1 k
(RC RP)Tj
T*
(EE PROG)Tj
ET
0 0 0 0 k
0.59 w []0 d
462.442 542.238 m
462.442 543.419 463.399 544.376 464.581 544.376 c
465.762 544.376 466.719 543.419 466.719 542.238 c
466.719 541.056 465.762 540.099 464.581 540.099 c
463.399 540.099 462.442 541.056 462.442 542.238 c
b
462.442 528.298 m
462.442 529.479 463.399 530.437 464.581 530.437 c
465.762 530.437 466.719 529.479 466.719 528.298 c
466.719 527.117 465.762 526.16 464.581 526.16 c
463.399 526.16 462.442 527.117 462.442 528.298 c
b
1.18 w
462.442 532.92 m
472.87 532.92 l
S
[1.18 1.18 ]0 d
462.442 546.971 m
472.87 546.971 l
S
[]0 d
505.798 569.18 m
505.798 565.111 l
487.257 569.18 m
487.257 565.111 l
468.716 569.18 m
468.716 565.111 l
450.175 569.18 m
450.175 565.111 l
431.405 569.18 m
431.405 565.111 l
412.864 569.18 m
412.864 565.111 l
394.551 569.18 m
394.551 565.111 l
394.551 672.903 111.247 -103.723 re
S
BT
7.9584 0 0 9.44 392.2625 556.1967 Tm
0 0 0 1 k
0.0598 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
0 9.44 -9.44 0 366.0926 594.7271 Tm
0 Tc
(V)Tj
0.593 0 TD
(alina sangre)Tj
9.44 0 0 9.44 373.2703 669.5072 Tm
(300)Tj
0 -2.1704 TD
(280)Tj
T*
(260)Tj
T*
(240)Tj
T*
(220)Tj
T*
(200)Tj
ET
391.743 652.588 m
394.623 652.588 l
391.743 630.819 m
394.623 630.819 l
391.743 611.578 m
394.623 611.578 l
391.743 591.253 m
394.623 591.253 l
S
[1.18 1.18 ]0 d
394.623 591.614 m
413.151 656.972 l
431.309 611.939 l
449.106 624.629 l
469.069 637.009 l
486.866 626.074 l
506.468 653.31 l
S
[]0 d
394.623 618.2 m
413.151 613.745 l
432.393 603.221 l
449.828 592.698 l
468.347 609.411 l
487.588 581.813 l
505.746 573.457 l
S
0 0 0 0 k
0.59 w
410.726 656.005 m
410.726 657.186 411.683 658.143 412.864 658.143 c
414.045 658.143 415.003 657.186 415.003 656.005 c
415.003 654.824 414.045 653.866 412.864 653.866 c
411.683 653.866 410.726 654.824 410.726 656.005 c
b
466.283 636.042 m
466.283 637.223 467.24 638.18 468.421 638.18 c
469.602 638.18 470.559 637.223 470.559 636.042 c
470.559 634.86 469.602 633.903 468.421 633.903 c
467.24 633.903 466.283 634.86 466.283 636.042 c
b
502.959 651.621 m
502.959 652.802 503.916 653.76 505.097 653.76 c
506.278 653.76 507.236 652.802 507.236 651.621 c
507.236 650.44 506.278 649.483 505.097 649.483 c
503.916 649.483 502.959 650.44 502.959 651.621 c
b
485.162 626.963 m
485.162 628.144 486.12 629.101 487.301 629.101 c
488.482 629.101 489.439 628.144 489.439 626.963 c
489.439 625.782 488.482 624.824 487.301 624.824 c
486.12 624.824 485.162 625.782 485.162 626.963 c
b
447.453 623.551 m
447.453 624.732 448.41 625.69 449.591 625.69 c
450.772 625.69 451.729 624.732 451.729 623.551 c
451.729 622.37 450.772 621.413 449.591 621.413 c
448.41 621.413 447.453 622.37 447.453 623.551 c
b
430.017 612.306 m
430.017 613.487 430.974 614.444 432.155 614.444 c
433.337 614.444 434.294 613.487 434.294 612.306 c
434.294 611.125 433.337 610.167 432.155 610.167 c
430.974 610.167 430.017 611.125 430.017 612.306 c
b
410.776 613.389 m
410.776 614.57 411.733 615.528 412.914 615.528 c
414.095 615.528 415.053 614.57 415.053 613.389 c
415.053 612.208 414.095 611.251 412.914 611.251 c
411.733 611.251 410.776 612.208 410.776 613.389 c
b
430.017 603.229 m
430.017 604.409 430.974 605.367 432.155 605.367 c
433.337 605.367 434.294 604.409 434.294 603.229 c
434.294 602.047 433.337 601.09 432.155 601.09 c
430.974 601.09 430.017 602.047 430.017 603.229 c
b
447.453 592.342 m
447.453 593.523 448.41 594.481 449.591 594.481 c
450.772 594.481 451.729 593.523 451.729 592.342 c
451.729 591.161 450.772 590.204 449.591 590.204 c
448.41 590.204 447.453 591.161 447.453 592.342 c
b
466.332 608.539 m
466.332 609.719 467.29 610.677 468.471 610.677 c
469.652 610.677 470.61 609.719 470.61 608.539 c
470.61 607.357 469.652 606.4 468.471 606.4 c
467.29 606.4 466.332 607.357 466.332 608.539 c
b
485.213 582.18 m
485.213 583.361 486.17 584.318 487.351 584.318 c
488.532 584.318 489.489 583.361 489.489 582.18 c
489.489 580.999 488.532 580.042 487.351 580.042 c
486.17 580.042 485.213 580.999 485.213 582.18 c
b
503.37 573.101 m
503.37 574.282 504.328 575.24 505.508 575.24 c
506.69 575.24 507.647 574.282 507.647 573.101 c
507.647 571.92 506.69 570.963 505.508 570.963 c
504.328 570.963 503.37 571.92 503.37 573.101 c
b
BT
9.44 0 0 9.44 436.4592 680.2681 Tm
0 0 0 1 k
(V)Tj
0.593 0 TD
(aline)Tj
-5.0249 -14.5625 TD
-0.0159 Tc
(ciclo)Tj
ET
1.18 w
190.98 395.85 m
190.98 391.74 l
170.424 395.85 m
170.424 391.74 l
149.868 395.85 m
149.868 391.74 l
129.311 395.85 m
129.311 391.74 l
108.502 395.85 m
108.502 391.74 l
87.945 395.85 m
87.945 391.74 l
67.642 395.85 m
67.642 391.74 l
67.642 500.633 123.338 -104.782 re
S
BT
8.7342 0 0 9.44 65.1045 382.8113 Tm
0.063 Tc
[(0 )-15.9(1 2 3 4 5 6)]TJ
ET
63.925 482.886 m
67.364 482.886 l
63.925 465.451 m
67.732 465.451 l
63.925 448.015 m
67.364 448.015 l
63.925 430.58 m
67.364 430.58 l
63.925 413.506 m
67.364 413.506 l
67.364 395.854 m
63.925 395.854 l
S
[1.18 1.18 ]0 d
67.364 403.44 m
87.764 473.945 l
107.824 423.205 l
129.064 477.19 l
149.124 450.64 l
170.954 481.91 l
190.424 472.175 l
S
[]0 d
67.364 438.545 m
87.764 437.955 l
108.414 418.485 l
128.769 445.92 l
148.829 470.995 l
170.364 484.27 l
190.424 489.58 l
S
0 0 0 0 k
0.59 w
85.231 472.693 m
85.231 473.873 86.189 474.831 87.37 474.831 c
88.551 474.831 89.508 473.873 89.508 472.693 c
89.508 471.512 88.551 470.554 87.37 470.554 c
86.189 470.554 85.231 471.512 85.231 472.693 c
b
85.231 437.588 m
85.231 438.769 86.189 439.726 87.37 439.726 c
88.551 439.726 89.508 438.769 89.508 437.588 c
89.508 436.406 88.551 435.449 87.37 435.449 c
86.189 435.449 85.231 436.406 85.231 437.588 c
b
106.176 417.233 m
106.176 418.414 107.134 419.371 108.315 419.371 c
109.496 419.371 110.453 418.414 110.453 417.233 c
110.453 416.052 109.496 415.094 108.315 415.094 c
107.134 415.094 106.176 416.052 106.176 417.233 c
b
126.826 475.348 m
126.826 476.528 127.784 477.486 128.965 477.486 c
130.146 477.486 131.103 476.528 131.103 475.348 c
131.103 474.167 130.146 473.209 128.965 473.209 c
127.784 473.209 126.826 474.167 126.826 475.348 c
b
126.236 444.963 m
126.236 446.144 127.194 447.101 128.375 447.101 c
129.556 447.101 130.513 446.144 130.513 444.963 c
130.513 443.782 129.556 442.824 128.375 442.824 c
127.194 442.824 126.236 443.782 126.236 444.963 c
b
105.586 424.018 m
105.586 425.198 106.544 426.156 107.725 426.156 c
108.906 426.156 109.863 425.198 109.863 424.018 c
109.863 422.837 108.906 421.879 107.725 421.879 c
106.544 421.879 105.586 422.837 105.586 424.018 c
b
147.181 470.038 m
147.181 471.218 148.139 472.176 149.32 472.176 c
150.501 472.176 151.458 471.218 151.458 470.038 c
151.458 468.857 150.501 467.899 149.32 467.899 c
148.139 467.899 147.181 468.857 147.181 470.038 c
b
147.181 449.978 m
147.181 451.159 148.139 452.116 149.32 452.116 c
150.501 452.116 151.458 451.159 151.458 449.978 c
151.458 448.797 150.501 447.839 149.32 447.839 c
148.139 447.839 147.181 448.797 147.181 449.978 c
b
168.421 484.198 m
168.421 485.378 169.379 486.336 170.56 486.336 c
171.741 486.336 172.698 485.378 172.698 484.198 c
172.698 483.017 171.741 482.059 170.56 482.059 c
169.379 482.059 168.421 483.017 168.421 484.198 c
b
169.306 480.068 m
169.306 481.249 170.264 482.206 171.445 482.206 c
172.626 482.206 173.583 481.249 173.583 480.068 c
173.583 478.887 172.626 477.929 171.445 477.929 c
170.264 477.929 169.306 478.887 169.306 480.068 c
b
189.071 471.808 m
189.071 472.988 190.029 473.946 191.21 473.946 c
192.391 473.946 193.348 472.988 193.348 471.808 c
193.348 470.627 192.391 469.669 191.21 469.669 c
190.029 469.669 189.071 470.627 189.071 471.808 c
b
189.366 488.918 m
189.366 490.099 190.324 491.056 191.505 491.056 c
192.686 491.056 193.643 490.099 193.643 488.918 c
193.643 487.737 192.686 486.779 191.505 486.779 c
190.324 486.779 189.366 487.737 189.366 488.918 c
b
BT
9.44 0 0 9.44 47.0679 496.4832 Tm
0 0 0 1 k
0 Tc
(180)Tj
0 -1.8359 TD
(160)Tj
T*
(140)Tj
T*
(120)Tj
T*
(100)Tj
0.5561 -1.8359 TD
(80)Tj
T*
(60)Tj
5.7952 12.633 TD
(Histidine)Tj
-4.2014 -14.9611 TD
-0.0159 Tc
0.0159 Tw
(cicl o)Tj
38.2377 14.898 TD
0 Tc
0 Tw
(T)Tj
0.5739 0 TD
(reonina)Tj
-17.3895 0.0396 TD
(T)Tj
0.5559 0 TD
(yrosine)Tj
ET
1.18 w
351.497 397.693 m
351.497 393.582 l
331.348 397.693 m
331.348 393.582 l
311.198 397.693 m
311.198 393.582 l
291.049 397.693 m
291.049 393.582 l
270.651 397.693 m
270.651 393.582 l
250.502 397.693 m
250.502 393.582 l
230.601 397.693 m
230.601 393.582 l
230.601 502.475 120.896 -104.782 re
S
BT
8.5613 0 0 9.44 228.1132 384.6537 Tm
0.063 Tc
[(0 )-15.8(1 2 3 4 5 6)]TJ
9.44 0 0 9.44 210.0017 499.212 Tm
0 Tc
(130)Tj
0 -1.3467 TD
(120)Tj
0.074 -1.3467 TD
-0.074 Tc
[(11)-74(0)]TJ
-0.074 -1.3467 TD
0 Tc
(100)Tj
0.5562 -1.3467 TD
(90)Tj
T*
(80)Tj
T*
(70)Tj
T*
(60)Tj
T*
(50)Tj
6.6148 0 0 7.08 321.8159 374.2486 Tm
(RC RP)Tj
0 -2 TD
(EE PROG)Tj
ET
0 0 0 0 k
0.59 w
308.753 374.75 m
308.753 375.931 309.71 376.888 310.891 376.888 c
312.072 376.888 313.03 375.931 313.03 374.75 c
313.03 373.569 312.072 372.612 310.891 372.612 c
309.71 372.612 308.753 373.569 308.753 374.75 c
b
308.753 360.81 m
308.753 361.991 309.71 362.949 310.891 362.949 c
312.072 362.949 313.03 361.991 313.03 360.81 c
313.03 359.629 312.072 358.672 310.891 358.672 c
309.71 358.672 308.753 359.629 308.753 360.81 c
b
1.18 w
308.753 365.432 m
319.181 365.432 l
S
[1.18 1.18 ]0 d
308.753 379.484 m
319.181 379.484 l
S
BT
9.44 0 0 9.44 230.2207 372.3605 Tm
0 0 0 1 k
-0.0159 Tc
0.0159 Tw
(cicl o)Tj
ET
230.768 432.127 m
250.238 488.767 l
271.183 435.962 l
290.358 440.387 l
311.008 437.732 l
330.773 449.827 l
351.718 434.782 l
S
[]0 d
228.408 489.357 m
230.768 489.357 l
228.408 475.787 m
230.178 475.787 l
228.408 463.692 m
230.768 463.692 l
228.408 449.532 m
230.768 449.532 l
228.408 435.962 m
230.473 435.962 l
228.408 423.651 m
230.768 423.651 l
228.408 409.963 m
230.473 409.963 l
230.473 397.696 m
228.408 397.696 l
230.44 428.635 m
250.657 440.749 l
270.985 433.425 l
291.285 433.425 l
311.39 479.065 l
331.161 424.987 l
351.155 409.421 l
S
0 0 0 0 k
0.59 w
248.202 487.397 m
248.202 488.578 249.159 489.536 250.34 489.536 c
251.521 489.536 252.479 488.578 252.479 487.397 c
252.479 486.216 251.521 485.259 250.34 485.259 c
249.159 485.259 248.202 486.216 248.202 487.397 c
b
248.87 440.644 m
248.87 441.825 249.828 442.782 251.009 442.782 c
252.19 442.782 253.147 441.825 253.147 440.644 c
253.147 439.463 252.19 438.506 251.009 438.506 c
249.828 438.506 248.87 439.463 248.87 440.644 c
b
269.644 436.217 m
269.644 437.398 270.601 438.355 271.782 438.355 c
272.963 438.355 273.921 437.398 273.921 436.217 c
273.921 435.036 272.963 434.078 271.782 434.078 c
270.601 434.078 269.644 435.036 269.644 436.217 c
b
268.864 432.791 m
268.864 433.972 269.821 434.929 271.002 434.929 c
272.183 434.929 273.141 433.972 273.141 432.791 c
273.141 431.61 272.183 430.652 271.002 430.652 c
269.821 430.652 268.864 431.61 268.864 432.791 c
b
289.304 440.31 m
289.304 441.491 290.261 442.448 291.442 442.448 c
292.623 442.448 293.581 441.491 293.581 440.31 c
293.581 439.129 292.623 438.171 291.442 438.171 c
290.261 438.171 289.304 439.129 289.304 440.31 c
b
288.717 432.791 m
288.717 433.972 289.675 434.929 290.856 434.929 c
292.037 434.929 292.994 433.972 292.994 432.791 c
292.994 431.61 292.037 430.652 290.856 430.652 c
289.675 430.652 288.717 431.61 288.717 432.791 c
b
309.045 436.774 m
309.045 437.955 310.003 438.912 311.184 438.912 c
312.365 438.912 313.322 437.955 313.322 436.774 c
313.322 435.593 312.365 434.635 311.184 434.635 c
310.003 434.635 309.045 435.593 309.045 436.774 c
b
329.205 448.466 m
329.205 449.647 330.162 450.604 331.343 450.604 c
332.524 450.604 333.482 449.647 333.482 448.466 c
333.482 447.285 332.524 446.327 331.343 446.327 c
330.162 446.327 329.205 447.285 329.205 448.466 c
b
349.086 434.853 m
349.086 436.034 350.043 436.991 351.224 436.991 c
352.405 436.991 353.363 436.034 353.363 434.853 c
353.363 433.672 352.405 432.714 351.224 432.714 c
350.043 432.714 349.086 433.672 349.086 434.853 c
b
329.594 424.494 m
329.594 425.676 330.552 426.633 331.733 426.633 c
332.914 426.633 333.871 425.676 333.871 424.494 c
333.871 423.313 332.914 422.356 331.733 422.356 c
330.552 422.356 329.594 423.313 329.594 424.494 c
b
350.004 409.216 m
350.004 410.397 350.962 411.355 352.143 411.355 c
353.324 411.355 354.282 410.397 354.282 409.216 c
354.282 408.035 353.324 407.078 352.143 407.078 c
350.962 407.078 350.004 408.035 350.004 409.216 c
b
308.961 479.098 m
308.961 480.279 309.918 481.237 311.099 481.237 c
312.28 481.237 313.238 480.279 313.238 479.098 c
313.238 477.917 312.28 476.96 311.099 476.96 c
309.918 476.96 308.961 477.917 308.961 479.098 c
b
1.18 w
503.025 398.497 m
503.025 394.415 l
485.306 398.497 m
485.306 394.415 l
467.587 398.497 m
467.587 394.415 l
449.868 398.497 m
449.868 394.415 l
431.93 398.497 m
431.93 394.415 l
414.211 398.497 m
414.211 394.415 l
396.711 398.497 m
396.711 394.415 l
396.711 502.549 106.314 -104.052 re
S
BT
7.5816 0 0 9.44 394.523 385.4963 Tm
0 0 0 1 k
0.0609 Tc
0 Tw
[(0 )-15.9(1 2 3 4 5 6)]TJ
9.44 0 0 9.44 377.025 499.2856 Tm
0 Tc
(200)Tj
0 -1.8142 TD
(180)Tj
T*
(160)Tj
T*
(140)Tj
T*
(120)Tj
T*
(100)Tj
0.5561 -1.8142 TD
(80)Tj
6.6148 0 0 7.08 488.2256 374.3222 Tm
(RC RP)Tj
0 -2 TD
(EE PRO)Tj
ET
q
26.73 691.61 490.35 -346.88 re
W* n
BT
6.6148 0 0 7.08 513.2218 360.1622 Tm
(G)Tj
ET
Q
0 0 0 0 k
0.59 w
475.162 374.824 m
475.162 376.005 476.12 376.962 477.301 376.962 c
478.482 376.962 479.44 376.005 479.44 374.824 c
479.44 373.643 478.482 372.685 477.301 372.685 c
476.12 372.685 475.162 373.643 475.162 374.824 c
b
475.162 360.884 m
475.162 362.065 476.12 363.023 477.301 363.023 c
478.482 363.023 479.44 362.065 479.44 360.884 c
479.44 359.703 478.482 358.746 477.301 358.746 c
476.12 358.746 475.162 359.703 475.162 360.884 c
b
1.18 w
475.162 365.506 m
485.591 365.506 l
S
[1.18 1.18 ]0 d
475.162 379.557 m
485.591 379.557 l
S
BT
9.44 0 0 9.44 396.6305 372.4341 Tm
0 0 0 1 k
-0.0159 Tc
0.0159 Tw
(cicl o)Tj
ET
[]0 d
394.818 489.431 m
397.178 489.431 l
394.818 475.861 m
396.588 475.861 l
394.818 463.766 m
397.178 463.766 l
394.818 449.606 m
397.178 449.606 l
394.818 436.036 m
396.883 436.036 l
394.818 423.724 m
397.178 423.724 l
394.818 410.037 m
396.883 410.037 l
396.883 397.77 m
394.818 397.77 l
S
0 0 0 0 k
0.59 w
495.615 448.539 m
495.615 449.72 496.572 450.678 497.753 450.678 c
498.934 450.678 499.891 449.72 499.891 448.539 c
499.891 447.358 498.934 446.401 497.753 446.401 c
496.572 446.401 495.615 447.358 495.615 448.539 c
b
BT
0 9.44 -9.44 0 204.521 420.9682 Tm
0 0 0 1 k
0 Tc
0 Tw
(T)Tj
0.5738 0 TD
(irosina sangre)Tj
-0.5721 -17.7824 TD
(T)Tj
0.5739 0 TD
(reonina sangre)Tj
ET
1.18 w [1.18 1.18 ]0 d
396.825 430.314 m
414.831 493.774 l
433.274 456.167 l
450.577 474.02 l
468.146 458.634 l
486.152 466.327 l
502.849 461.086 l
S
[]0 d
395.423 441.065 m
415.268 464.143 l
433.274 449.194 l
450.577 447.884 l
467.709 456.167 l
484.842 437.57 l
502.849 413.449 l
S
0 0 0 0 k
0.59 w
501.857 412.722 m
501.857 413.903 502.815 414.86 503.996 414.86 c
505.177 414.86 506.134 413.903 506.134 412.722 c
506.134 411.541 505.177 410.583 503.996 410.583 c
502.815 410.583 501.857 411.541 501.857 412.722 c
b
483.148 437.154 m
483.148 438.335 484.105 439.292 485.286 439.292 c
486.467 439.292 487.425 438.335 487.425 437.154 c
487.425 435.973 486.467 435.015 485.286 435.015 c
484.105 435.015 483.148 435.973 483.148 437.154 c
b
448.124 473.561 m
448.124 474.743 449.081 475.7 450.262 475.7 c
451.443 475.7 452.401 474.743 452.401 473.561 c
452.401 472.38 451.443 471.423 450.262 471.423 c
449.081 471.423 448.124 472.38 448.124 473.561 c
b
412.725 492.228 m
412.725 493.409 413.683 494.366 414.864 494.366 c
416.045 494.366 417.002 493.409 417.002 492.228 c
417.002 491.047 416.045 490.089 414.864 490.089 c
413.683 490.089 412.725 491.047 412.725 492.228 c
b
412.648 464.538 m
412.648 465.718 413.605 466.676 414.787 466.676 c
415.968 466.676 416.925 465.718 416.925 464.538 c
416.925 463.356 415.968 462.399 414.787 462.399 c
413.605 462.399 412.648 463.356 412.648 464.538 c
b
448.146 448.185 m
448.146 449.366 449.104 450.323 450.285 450.323 c
451.466 450.323 452.423 449.366 452.423 448.185 c
452.423 447.004 451.466 446.046 450.285 446.046 c
449.104 446.046 448.146 447.004 448.146 448.185 c
b
430.628 449.169 m
430.628 450.35 431.586 451.308 432.766 451.308 c
433.948 451.308 434.905 450.35 434.905 449.169 c
434.905 447.988 433.948 447.031 432.766 447.031 c
431.586 447.031 430.628 447.988 430.628 449.169 c
b
430.682 455.873 m
430.682 457.054 431.64 458.012 432.821 458.012 c
434.002 458.012 434.959 457.054 434.959 455.873 c
434.959 454.692 434.002 453.735 432.821 453.735 c
431.64 453.735 430.682 454.692 430.682 455.873 c
b
483.331 465.752 m
483.331 466.933 484.288 467.891 485.469 467.891 c
486.65 467.891 487.607 466.933 487.607 465.752 c
487.607 464.571 486.65 463.614 485.469 463.614 c
484.288 463.614 483.331 464.571 483.331 465.752 c
b
466.391 459.39 m
466.391 460.571 467.348 461.528 468.529 461.528 c
469.71 461.528 470.668 460.571 470.668 459.39 c
470.668 458.209 469.71 457.251 468.529 457.251 c
467.348 457.251 466.391 458.209 466.391 459.39 c
b
465.923 456.234 m
465.923 457.415 466.88 458.373 468.061 458.373 c
469.242 458.373 470.2 457.415 470.2 456.234 c
470.2 455.053 469.242 454.095 468.061 454.095 c
466.88 454.095 465.923 455.053 465.923 456.234 c
b
501.576 461.572 m
501.576 462.753 502.533 463.711 503.714 463.711 c
504.895 463.711 505.853 462.753 505.853 461.572 c
505.853 460.391 504.895 459.434 503.714 459.434 c
502.533 459.434 501.576 460.391 501.576 461.572 c
b
BT
0 9.44 -9.44 0 39.2328 417.7071 Tm
0 0 0 1 k
(Histidina sangre)Tj
ET
q
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.73 334.78 490.35 -36.78 re
f
BT
/F1 1 Tf
9 0 0 9 111.97 328.6251 Tm
0 0 0 1 k
-0.0001 Tc
0.0001 Tw
(Figure 2. Variation in AA following chemotherapy and according to tumor response \(II\).)Tj
ET
Q
endstream
endobj
26 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
/F3 17 0 R
/F4 18 0 R
/TT2 22 0 R
>>
/ExtGState <<
/GS1 8 0 R
/GS2 23 0 R
>>
>>
endobj
28 0 obj
<<
/Length 8677
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 285.1176 682.0326 Tm
0 0 0 1 k
/GS1 gs
-0.0002 Tc
0 Tw
(Discussion)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 295.8609 657.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0847 Tw
(Although the specificity of changes in AA levels)Tj
-0.9767 -1.1818 TD
0.1249 Tw
(in relation to tumor etiology is still not clearly de-)Tj
T*
0.125 Tw
(monstrated, it is evident that these increases return)Tj
T*
0.0842 Tw
[(to their normal values following an ef)17.8(ficacious the-)]TJ
T*
0.1007 Tw
[(rapy)64.9(, and increase again with disease relapse)]TJ
6.6 0 0 6.6 488.0292 609.6143 Tm
0 Tw
(13)Tj
11 0 0 11 494.6293 605.9843 Tm
0.1008 Tw
(. Ex-)Tj
-19.0465 -1.1818 TD
0.0063 Tc
0.1187 Tw
[(perimentally)64.9(, there have been specific patterns de-)]TJ
T*
-0.0001 Tc
0.0697 Tw
[(monstrated in the serum AA of rats in which speci-)]TJ
T*
0.0205 Tc
0.1045 Tw
(fic tumors had been experimentally induced, and)Tj
T*
0.075 Tc
0.2189 Tw
(which return to normal when the tumor is)Tj
T*
0.01 Tc
0 Tw
(extirpated)Tj
6.6 0 0 6.6 330.1955 544.6143 Tm
(14)Tj
11 0 0 11 336.9278 540.9843 Tm
0.1149 Tw
[(. For this reason that, in our study)64.9(, we)]TJ
-4.71 -1.1818 TD
0.0083 Tc
0.1167 Tw
(analyzed the serum AA at baseline and after each)Tj
T*
0 Tc
0.0899 Tw
(successive cycle of chemotherapy so as to generate)Tj
T*
0.0155 Tw
(a profile of the changes that may be useful in propo-)Tj
T*
0 Tw
(sing factors that could be predictive of recurrence. )Tj
0.9767 -1.1818 TD
0.1241 Tw
[(However)39.8(, clinical studies following this path are)]TJ
-0.9767 -1.1818 TD
0.0024 Tc
0.1226 Tw
(rare. The study by Elling et al)Tj
6.6 0 0 6.6 425.0772 466.6143 Tm
0 Tw
(22)Tj
11 0 0 11 431.7096 462.9843 Tm
0.1226 Tw
(, with a 2 year fo-)Tj
-13.3265 -1.1818 TD
0 Tc
0.0123 Tw
[(llow-up of patients with breast cancer)39.8(, correlated the)]TJ
T*
-0.0001 Tc
0.0267 Tw
[(changes in the AA profile with the disease recurren-)]TJ
T*
0.0026 Tc
0.1224 Tw
[(ce. Studies conducted after the sur)17.8(gical extirpation)]TJ
T*
0 Tc
0.026 Tw
(of tumors have demonstrated a normalization of AA)Tj
T*
0.0059 Tw
[(that, previously)65(, had been altered)]TJ
6.6 0 0 6.6 430.6604 401.6143 Tm
0 Tw
(24)Tj
11 0 0 11 437.2604 397.9843 Tm
-0.0001 Tc
0.006 Tw
(. Similar post-sur-)Tj
-13.8312 -1.1818 TD
0.0154 Tc
0.1096 Tw
(gical decreases in AA had been detected in other)Tj
T*
-0.0001 Tc
0 Tw
(studies)Tj
6.6 0 0 6.6 315.6684 375.6143 Tm
0 Tc
(25)Tj
11 0 0 11 326.2322 371.9843 Tm
0.1103 Tw
(and, although the patho-physiological me-)Tj
-3.7377 -1.1818 TD
0.0098 Tc
0.1152 Tw
(chanisms underlying these findings have not been)Tj
T*
0 Tc
0.1014 Tw
(delineated, the probable explanation may be due to)Tj
T*
0.1234 Tw
(the cessation of the tumor influence on the protein)Tj
T*
0 Tw
(metabolism of the host.)Tj
0.9767 -1.1818 TD
-0.065 Tc
(We)Tj
1.3375 0 TD
( )Tj
0.375 0 TD
0.0148 Tc
0.1102 Tw
(have not encountered, in the literature, any)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.77 719.95 m
517.12 719.95 l
S
0 0 0 0 k
26.77 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 26.7705 734.168 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(M. Cobo-Dols y cols.)Tj
ET
0 0 0 0 k
26.77 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 26.7705 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(26)Tj
ET
0 0 0 0 k
26.77 691.61 232.27 -41.44 re
f
BT
9 0 0 9 125.7864 685.4518 Tm
0 0 0 1 k
-0.0001 Tc
(TABLE I)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 47.8186 663.9449 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(AA after first chemotherapy cycle compared )Tj
7.2452 -1.0753 TD
(to baseline)Tj
ET
0 0 0 0 k
27.02 644.75 231.77 -335.07 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F5 1 Tf
9 0 0 9 109.8384 631.0389 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Overall)-9289(Non-)]TJ
-1.181 -1.1948 TD
0.0001 Tw
[(patient group)-985.4(Responders)-1124.6(Responders)]TJ
-7.2763 -1.1948 TD
0 Tc
0 Tw
[(Amino Acid)-4985.9(P)-5415.3(P)-5178.9(P)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
9 0 0 9 33.7225 588.0255 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(3-metylhistidine)-2791.4(NS)-4748.4(NS)-4512.1(NS)]TJ
0 -1.1948 TD
[(Aminobutyrate)-3055.8(0.04)-4512.3(NS)-4512.1(NS)]TJ
T*
-0.0002 Tc
0.0001 Tw
[(Aspartic acid)-4043.2(NS)-4748.5(NS)-4512.2(NS)]TJ
T*
0.0002 Tw
[(Glutamic acid)-3709.2(NS)-4748.5(NS)-4512.2(NS)]TJ
T*
0 Tc
0 Tw
[(Alanine)-5287.2(< 0.001)-2962.1(< 0.001)-3618.9(NS)]TJ
T*
-0.0001 Tc
0.0001 Tw
[(Arginine)-5305.3(0.004)-3369.2(< 0.001)-3619(NS)]TJ
T*
[(Asparagine)-4306.5(0.002)-3369.2(< 0.001)-3619(NS)]TJ
T*
-0.0002 Tc
0 Tw
[(Cysteine)-5846.4(NS)-4748.5(NS)-4512.2(NS)]TJ
T*
-0.0001 Tc
[(Citrulline)-5512.8(NS)-4512.3(0.01)-4039.9(0.02)]TJ
T*
0 Tc
[(Phenylalanine)-2787.6(< 0.001)-2962.1(< 0.001)-3132.8(0.004)]TJ
T*
-0.0001 Tc
[(Glycine)-5694.2(0.002)-3776.2(0.001)-4026(NS)]TJ
T*
0 Tc
[(Glutamine)-4231.5(< 0.001)-2962.1(< 0.001)-3382.8(0.03)]TJ
T*
-0.0001 Tc
0.0001 Tw
[(Hystidine)-4564.4(< 0.001)-2962.2(< 0.001)-3619(NS)]TJ
T*
-0.0002 Tc
0 Tw
[(Isoleucine)-5236.8(NS)-4262.4(0.007)-4026.1(NS)]TJ
T*
0 Tc
[(Leucine)-5232.2(< 0.001)-2962.1(< 0.001)-3618.9(NS)]TJ
T*
[(Lysine)-5731(< 0.001)-2962.1(< 0.001)-3618.9(NS)]TJ
T*
[(Methionine)-3842.3(< 0.001)-2962.1(< 0.001)-3618.9(NS)]TJ
T*
-0.0002 Tc
[(Hydroxyproline)-2958.7(NS)-4748.5(NS)-4512.2(NS)]TJ
T*
-0.0001 Tc
0.0001 Tw
[(Ornitine)-5527.5(0.009)-3369.2(< 0.001)-3619(NS)]TJ
T*
0 Tw
[(Proline)-5971.3(0.017)-3776.2(0.002)-4026(NS)]TJ
T*
0.0001 Tw
[(Serine)-5898.3(< 0.001)-2962.2(< 0.001)-3619(NS)]TJ
T*
0 Tw
[(Taurine)-6236.5(NS)-4512.3(0.04)-4276(NS)]TJ
T*
0 Tc
[(Tyrosine)-4898.2(< 0.001)-2962.1(< 0.001)-3382.8(0.02)]TJ
T*
[(Threonine)-4343.3(< 0.001)-2962.1(< 0.001)-2882.8(0.0027)]TJ
T*
[(Tryptophan)-3787.2(< 0.001)-3369.1(0.001)-3539.8(0.012)]TJ
T*
-0.0001 Tc
0.0001 Tw
[(Valine)-6444.2(0.01)-3619.2(< 0.001)-3619(NS)]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
27.02 644.75 231.77 -335.07 re
235.671 319.191 m
S
0 0 0 0 k
26.77 286.77 490.35 -34.39 re
f
BT
9 0 0 9 253.3277 280.6151 Tm
0 0 0 1 k
0 Tw
(TABLE II)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 112.823 259.1084 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(Comparisons of change \(%)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F4 1 Tf
10 0 0 10 228.7835 259.2584 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
()Tj
1 Tr
0 0 0 1 K
0 J 0 j 0.3 w 10 M []0 d
0 0 TD
()Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 234.7541 259.1084 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(\) in AA following the first chemotherapy cycle)Tj
ET
0 0 0 0 k
27.02 246.32 489.85 -173.95 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F5 1 Tf
9 0 0 9 33.7225 232.5172 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.0001 Tw
[(Amino Acid)-4522.5(Responders Versus Non-Responders)-3958.8(Amino Acid)-4084.7(Responders Versus Non-Responders)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
9 0 0 9 33.7225 211.0105 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(3-methyl-histidine)-8465.6(NS)-10887.9(Isoleucine)-10527.7(0.014)]TJ
0 -1.1948 TD
0 Tc
[(Aminobutyric acid)-8327.1(NS)-11332.1(Leucine)-10971.9(0.002)]TJ
T*
-0.0001 Tc
[(Aspartic acid)-10550.1(NS)-11581.6(Lysine)-11221.4(0.005)]TJ
T*
0 Tc
[(Glutamic acid)-10216(NS)-10637.2(Methionine)-10277(0.002)]TJ
T*
-0.0001 Tc
[(Alanine)-12201.2(0.007)-9262.8(Hydroxyproline)-9874.7(NS)]TJ
T*
[(Arginine)-11812.3(0.006)-11012.1(Proline)-11138(0.001)]TJ
T*
0.0001 Tw
[(Asparagine)-10406.5(< 0.001)-10772.1(Serine)-11555(0.02)]TJ
T*
0 Tw
[(Cysteine)-12353.3(NS)-11387.7(Taurine)-11513.6(NS)]TJ
T*
0 Tc
[(Citrulline)-11533.6(0.002)-10679(Tyrosine)-11054.9(0.02)]TJ
T*
[(Phenylalanine)-9701.6(0.001)-10401.6(Threonine)-10527.5(0.006)]TJ
T*
[(Glycine)-12451.1(0.01)-10373.5(Tryptophan)-10735.5(NS)]TJ
T*
-0.0001 Tc
[(Glutamine)-11631.6(NS)-11609.7(Valine)-11249.5(0.002)]TJ
T*
[(Hystidine)-11478.3(0.001)-10790.2(Ornitine)-10916.1(0.001)]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
27.02 246.32 489.85 -173.95 re
437.863 81.97 m
26.77 601.69 m
259.04 601.69 l
S
0 0 0 0 k
26.77 67.98 490.35 -11.33 re
f
BT
8 0 0 8 26.7705 58.3801 Tm
0 0 0 1 k
0.0001 Tw
(NS = not significant)Tj
ET
26.77 223.89 m
517.12 223.89 l
S
Q
endstream
endobj
29 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
/F3 17 0 R
/F4 18 0 R
/F5 30 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
32 0 obj
<<
/Length 8050
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.73 691.61 490.35 -634.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
11 0 0 11 26.7332 683.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.0045 Tw
(study that had analyzed the changes in the AA profi-)Tj
0 -1.1818 TD
0.0966 Tw
[(le with the use of chemotherapy)64.9(, and correlation of)]TJ
T*
0.0026 Tc
0.1224 Tw
(the findings with tumor response to the chemothe-)Tj
T*
0 Tc
0.0577 Tw
[(rapy)65(. W)79.9(e)0( began with the hypothesis that the respon-)]TJ
T*
0.0363 Tw
(der patients have significant changes in the AA pro-)Tj
T*
-0.0001 Tc
0.033 Tw
[(file relative to the non-responders. In the analysis of)]TJ
T*
0 Tc
0.0171 Tw
(each one of the AA following each cycle of chemot-)Tj
T*
-0.0001 Tc
0.0506 Tw
[(herapy we observed clear alterations in the AA pro-)]TJ
T*
0 Tc
0.0849 Tw
[(file of the responders with respect to the cycles ad-)]TJ
T*
0.0783 Tw
[(ministered; statistically significant dif)17.8(ferences in 21)]TJ
T*
-0.0001 Tc
0.1009 Tw
(AA in the responders while, in the non-responders,)Tj
T*
0 Tc
0 Tw
(the changes were significant in only 3 AA. )Tj
0.9767 -1.1818 TD
0.1054 Tw
(A very notable finding in our study is that when)Tj
-0.9767 -1.1818 TD
0.0434 Tw
[(we analyze the curves in AA profile changes during)]TJ
T*
0.0251 Tc
0.0999 Tw
[(the course of chemotherapy)64.9(, we observe that the)]TJ
T*
0 Tc
0.0298 Tw
(most significant changes are produced following the)Tj
T*
0.0099 Tc
0.1151 Tw
[(first cycle of chemotherapy)64.9(, and that this increase)]TJ
T*
0.012 Tc
0.113 Tw
(was much more evident in the responder than the)Tj
T*
0 Tc
0.0671 Tw
[(non-responder patients. In the responders, the chan-)]TJ
T*
0.0124 Tw
[(ges in the AA levels following the first cycle of che-)]TJ
T*
0.0138 Tw
(motherapy relative to baseline were significant in 20)Tj
T*
-0.0001 Tc
0.0721 Tw
[(AA while that in the non-responders these dif)17.8(feren-)]TJ
T*
0 Tc
0.0384 Tw
[(ces were only significant in 6 AA. In comparing the)]TJ
T*
-0.0001 Tc
0.0136 Tw
(responders with the non-responders, statistically sig-)Tj
T*
0.0241 Tw
[(nificant dif)17.7(ferences between the two sub-groups we-)]TJ
T*
0 Tc
0 Tw
(re observed in a total of 17 AA. )Tj
0.9767 -1.1818 TD
0.0446 Tw
(Based on the above observations, it would appear)Tj
-0.9767 -1.1818 TD
0.015 Tw
(that a decrease in the size of the tumor at least in the)Tj
T*
0.0601 Tw
(types of cancer studied and with the use of chemot-)Tj
T*
0.1093 Tw
(herapy based on cisplatin, clear changes in the AA)Tj
T*
0.01 Tw
(profile are induced, especially following the first cy-)Tj
T*
0.0203 Tw
[(cle. However)39.8(, our study was not able to demonstrate)]TJ
T*
0.0298 Tw
(whether the reduction or disappearance of the tumor)Tj
T*
0.0848 Tw
(results in a normalization of the AA that were alte-)Tj
T*
-0.0001 Tc
0.0175 Tw
[(red previously)64.8(. The progressive destruction of tumor)]TJ
T*
0.0233 Tc
0.1017 Tw
[(cells with the cytostatic agent produces dif)17.7(ferent)]TJ
T*
0 Tc
0.0362 Tw
(biochemical alterations that set in motion a series of)Tj
T*
0.0692 Tw
(mechanisms to re-utilize the products of tumor des-)Tj
T*
0.0466 Tw
(truction. This evidence for this is that these changes)Tj
T*
0.0057 Tc
0.1193 Tw
(and variations in the serum amino acid profile are)Tj
T*
0 Tc
0.0291 Tw
(noted in patients in whom the chemotherapy has be-)Tj
T*
0.0124 Tc
0.1125 Tw
[(en ef)17.8(fective and, as such, a greater availability of)]TJ
T*
0.0086 Tc
0.1163 Tw
(AA results as a consequence of the destruction of)Tj
T*
0.0138 Tc
0.1112 Tw
[(cellular proteins of the tumor and the decrease in)]TJ
T*
-0.0001 Tc
0 Tw
(their synthesis.)Tj
0.9767 -1.1818 TD
0 Tc
0.0152 Tw
(Hence, a rapid increase in the levels of circulating)Tj
-0.9767 -1.1818 TD
0.0336 Tc
0.0914 Tw
[(AA following the first cycle of a chemotherapy)]TJ
T*
-0.0001 Tc
0.0297 Tw
(scheme can serve as an early predictor of tumor res-)Tj
T*
0.0816 Tw
[(ponse. Further studies with a greater number of pa-)]TJ
23.4616 56.7273 TD
0.0109 Tc
0.1141 Tw
(tients including other histological types of tumors)Tj
0 -1.1818 TD
0.0003 Tc
0.1247 Tw
(and with other schemes of treatment are needed to)Tj
T*
-0.0001 Tc
0.0715 Tw
(confirm this hypothesis. Serial measurements of se-)Tj
T*
0.0143 Tc
0.1107 Tw
[(rum AA in cancer patients under)17.7(going chemothe-)]TJ
T*
0 Tc
0.0503 Tw
(rapy could provide an early prediction of the proba-)Tj
T*
0.0001 Tc
0.0049 Tw
[(bility of)17.9(f success of the treatment and, conversely)65(, to)]TJ
T*
0 Tc
0.0377 Tw
(modify the therapeutic approach if indices of proba-)Tj
T*
0 Tw
(ble of failure of the treatment are detected. )Tj
9 0 0 9 284.8106 530.2308 Tm
-0.0001 Tc
(Correspondence:)Tj
0 -1.1948 TD
(Manuel Cobo-Dols, MD )Tj
T*
0 Tc
(Seccin de Oncologa Mdica)Tj
T*
(Pabelln A, 3 planta Derecha)Tj
T*
(Secretara de Oncologa Mdica)Tj
T*
-0.0001 Tc
0.0001 Tw
(Hospital Regional Universitario Carlos Haya)Tj
T*
0 Tw
(Avda Carlos Haya, s/n)Tj
T*
0 Tc
(E-29010 Mlaga)Tj
T*
(E-mail: manuelcobodols@yahoo.es)Tj
T*
(E-mail \(alternative\):mangel.cobo.sspa@juntadeandalucia.es )Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 284.8106 371.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Refer)17.7(ences)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
9 0 0 9 289.3106 348.231 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0.113 Tw
[(1.)-661.7(Jope EM . The emergence of man: information from pro-)]TJ
1.4117 -1.1948 TD
0.1208 Tw
(tein systems. Philosophical Transactions of the Royal So-)Tj
T*
0.1058 Tw
(ciety of London - Series B: Biological Sciences 1981;292)Tj
T*
-0.0001 Tc
0 Tw
(\(1057\):121-131.)Tj
-1.4117 -1.4338 TD
0 Tc
0.0446 Tw
[(2.)-661.7(Scriver CR, Lamm P, Clow CL. Plasma amino acids: scre-)]TJ
1.4117 -1.1948 TD
0.0265 Tc
0.0985 Tw
(ening, quantitation, and interpretation. Am J Clin Nutr)Tj
T*
0 Tc
0 Tw
(1971;24\(7\):876-890.)Tj
-1.4117 -1.4338 TD
0.0434 Tw
[(3.)-661.7(Frommel C. The apolar surface area of amino acids and its)]TJ
1.4117 -1.1948 TD
0.0582 Tw
(empirical correlation with hydrophobic free energy. J The-)Tj
T*
0 Tw
(or Biol 1984;111\(2\):247-260.)Tj
-1.4117 -1.4338 TD
(4.)Tj
1.4117 0 TD
0.0054 Tc
0.1196 Tw
(Lochmuller CH, Souter RW. Chromatographic resolution)Tj
0 -1.1948 TD
0.0003 Tc
0.1247 Tw
(of enantiomers selective review. J Chromatography 1975;)Tj
T*
0 Tc
0 Tw
(113:283-302.)Tj
-1.4117 -1.4338 TD
0.1127 Tw
[(5.)-661.7(Morris DR, Fillingame RH. Regulation of amino acid de-)]TJ
1.4117 -1.1948 TD
0 Tw
(carboxylation. Ann Rev Biochem 1974;43:303-325.)Tj
-1.4117 -1.4338 TD
0.0817 Tw
[(6.)-661.7(Fleschmann W. The metabolism of damaged cells and tis-)]TJ
1.4117 -1.1948 TD
0.0053 Tc
0.1197 Tw
(sues. Cold Spring Harbor Symposia on Cuantitative Bio-)Tj
T*
0 Tc
0 Tw
(logy 1989;7: 290-300.)Tj
-1.4117 -1.4338 TD
(7.)Tj
1.4117 0 TD
0.021 Tc
0.1039 Tw
(Lanza-Jacoby S, Lansey S, Miller EE, Clearly MP. Se-)Tj
0 -1.1948 TD
0 Tc
0.1129 Tw
(quential changes in the activities of lipoptotein lipase and)Tj
T*
0.0053 Tw
(lipogenic enzymes during tumor growth in rats. Cancer Res)Tj
T*
0 Tw
(1984;44: 5062-5067.)Tj
-1.4117 -1.4338 TD
0.0259 Tw
[(8.)-661.7(Lundholm K, Bylund AC, Schersten T. Skeletal mucle me-)]TJ
1.4117 -1.1948 TD
0.0105 Tc
0.1145 Tw
(tabolism in patients with malignant tumor. Eur J Cancer)Tj
T*
0 Tc
0 Tw
(1976;12: 465-473.)Tj
-1.4117 -1.4338 TD
0.106 Tw
[(9.)-661.7(Holt LE, Snyderman SE, Norton PM, Roiman E, Finch J.)]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.74 719.95 m
517.08 719.95 l
S
0 0 0 0 k
26.73 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 382.1097 734.168 Tm
0 0 0 1 k
/GS1 gs
0 Tc
-0.0001 Tw
(Oncologa, 2005; 28 \(7\):321-328)Tj
ET
0 0 0 0 k
493.07 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 507.0804 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(27)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
402 566.88 m
517.08 566.88 l
S
Q
endstream
endobj
33 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
35 0 obj
<<
/Length 4968
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 691.61 490.35 -295.96 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
9 0 0 9 43.9756 685.4518 Tm
0 0 0 1 k
/GS1 gs
0.0205 Tc
0.1045 Tw
(The plasma aminogram in kwashiorkor. Lancet 1963;2:)Tj
0 -1.1948 TD
0 Tc
0 Tw
(1343-1348.)Tj
-1.9117 -1.4338 TD
0.0033 Tc
0.1216 Tw
[(10.)-658.4(Clark EF, Lewis AM, Waterhose C. Periferal amino acid)]TJ
1.9117 -1.1948 TD
0 Tc
0 Tw
(levels in patients with cancer. Cancer 1978;42:2909-2913.)Tj
-1.9117 -1.4338 TD
(11.)Tj
1.9117 0 TD
0.0231 Tc
0.1018 Tw
(Kern KA, Norton JA. Cancer cachexia. JPEN 1988;12:)Tj
0 -1.1948 TD
0 Tc
0 Tw
(286-298.)Tj
-1.9117 -1.4338 TD
-0.0001 Tc
0.0468 Tw
[(12.)-661.8(Russell DM, Shike M, Anderson GH. Amino acid metabo-)]TJ
1.9117 -1.1948 TD
0.0296 Tc
0.0954 Tw
(lism in small cell lung cancer. J Parenter Enteral Nutr)Tj
T*
0 Tc
0 Tw
(1981;6:592.)Tj
-1.9117 -1.4338 TD
0.0986 Tw
[(13.)-661.7(Elling D, Bader K, Schicke B. Free serum amino acids in)]TJ
1.9117 -1.1948 TD
-0.0001 Tc
0.0419 Tw
[(patientts with tumors of different sites - tumor induced im-)]TJ
T*
0 Tc
0 Tw
(balances. Zentralbl Gynakol 1987;109:1023-1032.)Tj
-1.9117 -1.4338 TD
-0.0001 Tc
0.0817 Tw
[(14.)-661.8(Kuzer M, Janizewski J, Meguid MM. Amino acid profiles)]TJ
1.9117 -1.1948 TD
0.0075 Tc
0.1175 Tw
(in tumor-bearing and pair-fed nontumor-bearing malnou-)Tj
T*
0 Tc
0 Tw
(rished rats. Cancer 1988;62:30-)Tj
-1.9117 -1.4338 TD
-0.0001 Tc
0.0192 Tw
[(15.)-661.8(Landel AM, Hammond WG, Meguid MM. Aspects of ami-)]TJ
1.9117 -1.1948 TD
0.0092 Tc
0.1158 Tw
(no acid and protein metabolism in cancer bearing states.)Tj
T*
0 Tc
0 Tw
(Cancer 1985;55:230-237.)Tj
-1.9117 -1.4338 TD
(16.)Tj
1.9117 0 TD
0.0299 Tc
0.095 Tw
(Landel AM, Lo CC, Meguid MM, Rivera D. Effect of)Tj
0 -1.1948 TD
0.0191 Tc
0.1059 Tw
(metyl-colanthrene- induced sarcoma and its removal on)Tj
T*
0.0251 Tc
0.0999 Tw
(rats and intracelular free amino acid content. Surg Res)Tj
T*
0 Tc
0 Tw
(Commun 1987;1:273-287.)Tj
-1.9117 -1.4338 TD
0.0445 Tw
[(17.)-661.7(Cascino A, Cangiano C, Ceci F, Franchi F, Menichetti ET,)]TJ
1.9117 -1.1948 TD
0.047 Tw
(Muscaritoli M. Plasma aminoacid in human cancer: the in-)Tj
T*
0.0696 Tw
(dividual role of tumor, malnutrition and glucose tolerance.)Tj
T*
0 Tw
(Clin Nutr 1988;7:213-218.)Tj
26.7636 31.7818 TD
0.1168 Tw
[(18.)-661.7(Meguid MM, Muscaritoli, Beverly Jl, Yang ZJ, Cangiano)]TJ
1.9117 -1.1948 TD
0.0201 Tc
0.1049 Tw
(C, Rosi Fanelli F. The early cancer anorexia paradigm:)Tj
T*
0.0009 Tc
0.1241 Tw
(changes in plasma free tryptophan and feeding indexes. J)Tj
T*
-0.0001 Tc
0 Tw
(Parent Enteral Nutr 1992;16:56S-59S.)Tj
-1.9117 -1.4338 TD
0 Tc
0.0761 Tw
[(19.)-661.7(Cascino A, Cangiano C, Ceci F, Franchi F, Mineo T, Mu-)]TJ
1.9117 -1.1948 TD
0.0092 Tc
0.1158 Tw
(lieri M. Increased plasma free tryptofan levels in human)Tj
T*
0.0047 Tc
0.1203 Tw
(cancer: a tumor releated effect? Anticancer Res 1991;11:)Tj
T*
0 Tc
0 Tw
(1313-1316.)Tj
-1.9117 -1.4338 TD
(20.)Tj
1.9117 0 TD
0.0219 Tc
0.1031 Tw
(Cascino A, Muscaritoli M, Cangiano C, Conversano L.)Tj
0 -1.1948 TD
0 Tc
0.0296 Tw
(Plasma aminoacid imbalance in patients with lung and bre-)Tj
T*
0 Tw
(ast cancer. Anticancer Res 1995;15:507-510.)Tj
-1.9117 -1.4338 TD
0.0322 Tw
[(21.)-661.7(Elling, Bader K, Schicke B. Use of free serum amino acids)]TJ
1.9117 -1.1948 TD
0.12 Tw
(in therapy monitoring of patients with treated vulvar can-)Tj
T*
0 Tw
(cer. Zentralbl Gynakol 1987;109:654-662.)Tj
-1.9117 -1.4338 TD
0.0091 Tw
[(22.)-661.7(Elling D, Bader K. Therapeutic monitoring of breast cancer)]TJ
1.9117 -1.1948 TD
-0.0001 Tc
0.0576 Tw
(patients by means of free serum amino acids. Arch Gesch-)Tj
T*
0 Tw
(wulstforsch 1986;56:23-33.)Tj
-1.9117 -1.4338 TD
0 Tc
0.0677 Tw
[(23.)-661.7(Zhang PC, Pang CP. Plasma aminoacid patterns in cancer.)]TJ
1.9117 -1.1948 TD
0 Tw
(Clin Chem 1992;38:1198-1199.)Tj
-1.9117 -1.4338 TD
-0.0001 Tc
0.1053 Tw
[(24.)-661.8(Naini AB, Dickerson JWT, Brown MM. Preoperative and)]TJ
1.9117 -1.1948 TD
0.0062 Tc
0.1188 Tw
(postoperative levels of plasma protein and amino acid in)Tj
T*
0 Tc
0.0907 Tw
(esophageal and lung cancer patients. Cancer 1988;62:355-)Tj
T*
0 Tw
(360.)Tj
-1.9117 -1.4338 TD
-0.0001 Tc
0.0544 Tw
[(25.)-661.8(Dale G, Young F, Latner AL, Goode A, Tweedle D, John-)]TJ
1.9117 -1.1948 TD
0 Tc
0.045 Tw
(ton IDA. The efect of surgical operation on venous plasma)Tj
T*
0 Tw
(free amino acids. Surgery 1977;81:295-301.)Tj
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.77 719.95 m
517.12 719.95 l
S
0 0 0 0 k
26.77 788 490.35 -56 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
10 0 0 10 26.7705 734.168 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
(M. Cobo-Dols y cols.)Tj
ET
0 0 0 0 k
26.77 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 26.7705 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(28)Tj
ET
Q
endstream
endobj
36 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
>>
/ExtGState <<
/GS1 8 0 R
>>
>>
endobj
8 0 obj
<<
/Type /ExtGState
/SA false
/SM 0.02
/TR /Identity
>>
endobj
23 0 obj
<<
/Type /ExtGState
/SA true
/SM 0.02
/TR /Identity
>>
endobj
37 0 obj
<<
/Type /FontDescriptor
/Ascent 0
/CapHeight 0
/Descent 0
/Flags 32
/FontBBox [20 -9 714 689]
/FontName /FPPMLL+Europatch
/ItalicAngle 0
/StemV 85
/StemH 92
/CharSet (/A)
/FontFile3 38 0 R
>>
endobj
38 0 obj
<<
/Length 297
/Subtype /Type1C
>>
stream
FPPMLL+Europatch ^E %.Copyright 1998 Apple Computer Inc.Europatch " |c\Y^G6))8iHH]]mU}N<rQErRNU]Hi֥CL@i3:GRhs}=VcϨhFx{ARcy
endstream
endobj
39 0 obj
<<
/Type /FontDescriptor
/Ascent 770
/CapHeight 718
/Descent -229
/Flags 32
/FontBBox [-166 -225 1000 931]
/FontName /Helvetica
/ItalicAngle 0
/StemV 88
/XHeight 523
/StemH 88
>>
endobj
6 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 40 0 R
/BaseFont /Times-Roman
/ToUnicode 41 0 R
>>
endobj
7 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 42 0 R
/BaseFont /Times-Bold
/ToUnicode 43 0 R
>>
endobj
17 0 obj
<<
/Type /Font
/Subtype /Type1
/FirstChar 65
/LastChar 65
/Widths [750 ]
/Encoding /WinAnsiEncoding
/BaseFont /FPPMLL+Europatch
/FontDescriptor 37 0 R
>>
endobj
18 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 44 0 R
/BaseFont /Symbol
/ToUnicode 45 0 R
>>
endobj
30 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 46 0 R
/BaseFont /Times-Italic
/ToUnicode 47 0 R
>>
endobj
22 0 obj
<<
/Type /Font
/Subtype /TrueType
/FirstChar 32
/LastChar 121
/Widths [278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
556 556 556 556 556 556 556 556 556 556 0 0 0 0 0 0
0 667 0 722 0 667 611 778 722 0 0 0 556 833 0 778
667 0 722 0 611 0 667 0 0 0 0 0 0 0 0 0
0 556 0 500 556 556 0 556 556 222 0 0 222 0 556 556
556 0 333 500 278 556 0 0 0 500 ]
/Encoding /WinAnsiEncoding
/BaseFont /Helvetica
/FontDescriptor 39 0 R
>>
endobj
40 0 obj
<<
/Type /Encoding
/Differences [ 32/space 37/percent/ampersand 40/parenleft/parenright 43/plus/comma/hyphen
/period/slash/zero/one/two/three/four/five
/six/seven/eight/nine/colon/semicolon/less/equal
/greater/question/at/A/B/C/D/E
/F/G/H/I/J/K/L/M
/N/O/P/Q/R/S/T/U
/V/W/X/Y/Z 97/a/b/c
/d/e/f/g/h/i/j/k
/l/m/n/o/p/q/r/s
/t/u/v/w/x/y/z 128/bullet
133/endash 141/quotedblleft/quotedblright 144/quoteright 176/degree 186/ordmasculine 225/aacute 233/eacute
237/iacute 243/oacute
]
>>
endobj
42 0 obj
<<
/Type /Encoding
/Differences [ 32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period 48/zero
/one/two/three 53/five 55/seven/eight 58/colon/semicolon
65/A/B/C/D/E/F/G 73/I
/J/K/L/M 79/O/P 82/R/S
/T 86/V 97/a/b/c/d/e/f
/g/h/i/j 108/l/m/n/o
/p 114/r/s/t/u/v/w 121/y
/z 128/bullet 233/eacute 237/iacute 243/oacute
]
>>
endobj
44 0 obj
<<
/Type /Encoding
/Differences [ 1/Delta 32/space 181/mu
]
>>
endobj
46 0 obj
<<
/Type /Encoding
/Differences [ 32/space 45/hyphen 65/A 78/N/O/P 82/R 86/V
97/a 99/c/d/e 103/g 105/i 108/l/m
/n/o/p 114/r/s/t/u/v
]
>>
endobj
41 0 obj
<<
/Filter /FlateDecode
/Length 316
>>
stream
HTn0E|,Sua숔HI)>Ԥ{HY;cT]`q5#u0#NvK0
;R4izAP:N\;@Ue)\a`1t$x{tP`Y#NNW]vgJ5Tt[&ҴK,9dVREd$^']F'~$FI2s<;bvDdlvPI*TB*ILBC\jC{?$aJnZbr<^m=29_# 3`T
endstream
endobj
43 0 obj
<<
/Filter /FlateDecode
/Length 364
>>
stream
HTMo0
7 $@vz؇nw
C!
?;: y$kˉo~j@?<}p`!U
r݅;6b
_ǝ'(~y۪Wߡ 'ٹo.@]C}Ҍ1!OSkZ=!T*u
hgQ)Ǿj|$7ҹ蜴YEдDUUi\b݉ސfc[]GuJQ3I
Z(`5dԆA)0h<Rҙ 46Ȥzҹtm; sM (0#!f8Ĉ.FBHK'Om{sx;a